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Abstract
A series of nine tetrahydroacridine derivatives with iodobenzoic moiety were synthesized and evaluated for their cytotoxic 
activity against cancer cell lines—A549 (human lung adenocarcinoma), HT-29 (human colorectal adenocarcinoma) and 
somatic cell line—EA.hy926 (human umbilical vein cell line). All compounds displayed high cytotoxicity activity against 
A549  (IC50 59.12–14.87 µM) and HT-29  (IC50 17.32–5.90 µM) cell lines, higher than control agents—etoposide and 5-fluo-
rouracil. Structure–activity relationship showed that the position of iodine in the substituent in the para position and longer 
linker most strongly enhanced the cytotoxic effect. Among derivatives, 1i turned out to be the most cytotoxic and displayed 
 IC50 values of 14.87 µM against A549 and 5.90 µM against HT-29 cell lines. In hyaluronidase inhibition assay, all compounds 
presented anti-inflammatory activity, however, slightly lower than reference compound. ADMET prediction showed that 
almost all compounds had good pharmacokinetic profiles. 1b, 1c and 1f compounds turned out to act against chemoresist-
ance in cisplatin-resistant 253J B-V cells. Compounds intercalated into DNA and inhibited cell cycle in G0/G1 phase—the 
strongest inhibition was observed for 1i in A549 and 1c in HT-29. Among compounds, the highest apoptotic effect in both 
cell lines was observed after treatment with 1i. Compounds caused DNA damage and H2AX phosphorylation, which was 
detected in A549 and HT-29 cells. All research confirmed anticancer properties of novel tetrahydroacridine derivatives and 
explained a few pathways of their mechanism of cytotoxic action.
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Introduction
It was estimated that there would be 18.1 million new cases 
and 9.6 million cancer deaths worldwide in 2018. Lung 
cancer affects 2.1 million people (11.6% of total cases) and 
causes death of 1.76 million (18.4% of total cancer deaths). 
These numbers give lung cancer number one among all 
cases, and it is the leading cause of cancer deaths world-
wide. Colorectal cancer (CRC) would be responsible for 1.8 
million new cases (10.3% of total incidents) and for 0.88 
million (9.2% of total cancer deaths) of mortality due to the 
cancer. It gives colon cancer third place among all new cases 
and second cause of death. New cancer cases and mortality 
are growing worldwide [1]. Chemotherapy has many side 
effects such as pain, vomiting, diarrhoea, stomatitis, vascu-
lar and neuronal damage. Moreover, anticancer drugs pos-
sess poor bioavailability, fast renal clearance and can induce 
resistance [2–4]. Among drugs using to treat colon cancer, 
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5-fluorouracil (5-FU) is the basic one. It inhibits DNA rep-
lication and further blocks the growth of cancer cells [2, 5]. 
Etoposide is an anticancer drug which is the topoisomerase 
II inhibitor [6, 7]. Etoposide is used to treat lung cancer, 
testicular cancer, lymphoma or glioblastoma multiform 
[8]. Anticancer agents, such as etoposide, bleomycin and 
doxorubicin, damage the vascular endothelium. Because of 
these treatments, which can lead to necrosis or apoptosis, 
the endothelium loses its integrity and preservation of many 
functions [9].
Acridines have a long story of being therapeutic com-
pounds. They are known as antibacterial, antiviral and anti-
cancer agents [10]. Nowadays, the most common acridine 
derivative is amsacrine, which is used as antineoplastic 
agents in the treatment of leukaemia. Moreover, research-
ers around the world have studied novel acridine derivatives 
against various cancers [11–17]. The mechanism of action 
of acridine derivatives involves intercalation into DNA in 
the space between two base pairs, due to the planar polycy-
clic aromatic structure. Intercalation results in unwinding 
of double helix and lengthening of the DNA strand. These 
changes can cause retardation or inhibition of transcription 
and replication, which is a good feature in cancer treatment, 
but might result in mutagenic activity in somatic cells. [18].
Oxidative stress has a role in cancer development. Can-
cer itself increases oxidative stress. In cancer cells, oxida-
tive stress is associated with mitochondrial dysfunction, 
increased levels of reactive oxygen species (ROS) and higher 
metabolic activity. Moreover, oxidative stress in cancer 
cells stimulates cellular proliferation, promotes mutations 
and alternates cell’s sensitivity to anticancer agents. Some 
chemotherapeutic agents can generate ROS in patients’ cells 
during treatment [19]. ROS is important for the induction 
of apoptosis in many cancer cells [20], and can cause DNA 
damage [21]. Antioxidants inhibit ROS generation and some 
might say that by this way, use of antioxidants can prevent 
apoptosis in cancer cells. There is a different opinion of the 
use of antioxidants during anticancer treatment [22, 23], 
because anticancer agents generate ROS and antioxidants 
may prevent cancer cells by inhibiting ROS generation. 
Therefore, it is believed that simultaneously use of anti-
oxidants should be avoided during cancer treatment [24]. 
However, except for three interferences (tangeretin with 
tamoxifen, NAC with doxorubicin and beta-carotene with 
5-fluorouracil), many data show the increase in effectiveness 
as well as decrease of side effects of chemotherapeutic drugs 
when administrated with antioxidants [25]. Even though 
many anticancer drugs induce ROS, their anticancer effects 
do not only depend on free radicals [26–28]. Although clini-
cal studies on the effect of antioxidants in cancer treatment 
are limited, experimental studies show that antioxidant vita-
mins could induce apoptosis in cancer cells, prevent angio-
genesis and metastatic spread. This could have an impact 
on potential role of antioxidants as adjuvants in anticancer 
therapy [29].
Studies on biodistribution of tetrahydroacridine deriva-
tives with similar structure showed that these compounds 
accumulate mainly in the rat’s lungs and intestines [30]. A 
series of novel tetrahydroacridine and cyclopentaquinoline 
derivatives with fluorobenzoic acid moieties were synthe-
sized and evaluated for their anticancer properties by our 
research team previously [13, 31]. Results became the basis 
for further researches in this direction. In current study, we 
evaluated next group of tetrahydroacridine derivatives—
the ones with iodobenzoic moieties. Moreover, benzoic 
acid derivatives possess antioxidant activities [32]. Due to 
the iodobenzoic moiety, we checked if our compound with 
iodobenzoic moiety has its role in antioxidant action. The 
influence of novel kind of moieties on anticancer activities 
of tetrahydroacridine derivatives was investigated. The syn-
thesis of novel tetrahydroacridine compounds with iodoben-
zoic acid moiety was described previously [33]. The aim of 
this study was to determine the cytotoxic activity of 9 novel 
tetrahydroacridine derivatives on A549, HT-29 cell lines, to 
investigate their biological properties and molecular mecha-
nism of action.
Materials and methods
Synthesis of tetrahydroacridine derivatives
The synthesis of novel tetrahydroacridine derivatives with 
iodobenzoic moieties (Scheme 1) was described previously 
in publication by Skibiński et al. [33]. At the beginning, 
the 2-chloro-4,6-dimethyl-1,3,5-triazine (CDMT) in THF 
(10 mL), 2-iodobenzoic acid, 3-iodobenzoic acid or 4-iodo-
benzoic acid and dropwise N-methylmorpholine were mixed 
together at temperature − 10 °C. Mixture was stirred for 2 h. 
Then amines (0.16–0.36 g) dissolved in THF (5 mL),were 
added at − 10 °C to the mixture. Stirring was continued at 
room temperature for 24 h. Obtained compounds were puri-
fied by flash chromatography. In order to get hydrochloride 
salts, compounds were dissolved in methanol (0.5 mL) and 
then HCl/ether (10 mL) was added. Firstly, mixture was 
stirred at room temperature for 30 min and then was stirred 
overnight to form solid. The compounds were isolated by 
filtration and dried.
ADMET analysis
Absorption, distribution, metabolism, elimination and tox-
icity (ADMET) analysis describes predictable disposal of 
novel compounds within the body. During the development 
of new drugs, it is crucial to find out, whether compounds 
violate Lipinski’s rule of five, or cause genotoxicity and 
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cardiotoxicity. Lipinski’s rule of five is used to evaluate 
pharmacological and biological activities which determine 
likeness of being orally active drugs. ADMET predictions 
were calculated using ACD/Percepta 14.0.0 [34].
Cell culture
A549 cell line (lung carcinoma from human) (European 
Collection of Cell Culture) and HT-29 cell line (colorectal 
adenocarcinoma from human) (American Type Culture Col-
lection) were chosen to evaluate the cytotoxicity of novel 
compounds. A549 cells were grown in Dulbecco’s Modi-
fied Eagle’s Medium (PAN-Biotech) containing 10% Fetal 
Bovine Serum (FBS) (Sigma Aldrich), 2 mM Glutamine 
(Sigma Aldrich) and 100 units/mL penicillin and 100 mg/
mL streptomycin (Sigma Aldrich).
HT-29 cells were grown in McCoy’s Medium (Biologi-
cal Industries) containing 10% FBS (Sigma Aldrich), 2 mM 
Glutamine (Sigma Aldrich) and 100 units/mL penicillin and 
100 mg/mL streptomycin (Sigma Aldrich).
The EA.hy926 cells (the human umbilical vein, somatic 
cell hybrid) (American Type Culture Collection) are immor-
talized human umbilical vein endothelial cells. They have 
morphological, phenotypic and functional characteristics of 
human endothelial cells, without the limited lifespan. This 
cell line has been considered as a good model for anticancer 
drug screening [35] and was chosen to evaluate the endothe-
lial cytotoxicity of novel compounds. Cells were grown in 
Dulbecco’s Modified Eagle’s Medium (PAN-Biotech) con-
taining 10% FBS (Sigma Aldrich), 2 mM Glutamine (Sigma 
Aldrich) and 100 units/mL penicillin and 100 mg/mL strep-
tomycin (Biological Industries).
253J B-V (human bladder cancer) (kindly provided by 
Dr Colin Dinney—MD Anderson Cancer Center) and 253J 
B-V cisplatin-resistant cells (253J B-V Cr) were chosen to 
evaluate if novel compounds were cytotoxic to sensitive 
and chemoresistant cells. Cells were grown in RPMI 1640 
medium (EuroClone), supplementing with 10% FBS (Euro-
Clone), 100 units/mL penicillin and 100 mg/mL streptomy-
cin (EuroClone).
Induction of Cisplatin resistance was induced as previ-
ously described—resistance to cisplatin was induced by 
adding 253J B-V cells to various concentrations of cisplatin 
(0.5; 0.8; 1; 1.3; 1.5 μg/mL). Each concentration was tested 
for at least 6 weeks. After this time, cells stayed for at least 
1 month without addition of the drug. When they started to 
proliferate again, cisplatin concentration was increased to 
the highest dose. It took a year to induce resistance to the 
highest cisplatin concentration [36].
The SH-SY5Y (human neuroblastoma) (European Col-
lection of Cell Culture) was chosen to evaluate the pro-
tection from oxidative stress. Cells were grown in Ham’s 
F12:EMEM (1:1) (Sigma Aldrich) containing 2 mM Glu-
tamine (Sigma Aldrich), 1% Non-Essential Amino Acids 
(Biological Industries), 15% FBS (Biowest) and 100 units/
mL penicillin and 100 mg/mL streptomycin (Biological 
Industries).
All cell lines grown in an incubator at 37 °C with 5%  CO2 
to 80% confluence before the initiation of the assay.
MTT cytotoxicity assay
The MTT assay was used to evaluate cell metabolic activity. 
The test principle is based on the determination of cell via-
bility by measuring the metabolic activity in mitochondria. 
Enzymatically active mitochondria reduce the water-soluble 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium-
bromide) to blue–violet insoluble formazan. The number of 
viability cells is proportional to the colour intensity deter-
mined by photometric measurements (an analytical wave-
length 570 nm) after dissolving the formazan in Dimethyl-
sulfoxide (DMSO) (Serva) and Sorensen’s glycine buffer. 
MTT (Sigma Aldrich) was dissolved in Phosphate Buffered 
Saline (PBS) (PAN-Biotech) at a concentration of 0.5 mg/
mL. Sorensen’s glycine buffer is made of 0.1 M glycine and 
0.1 M NaCl, at pH 10.5. Studied compounds were dissolved 
in DMSO in order to receive stock solutions.
For the assay, cells were seeded into 96-well plates at 
density  104 cells per well and cultured for 24 h at 37 °C and 
5%  CO2. Then medium was removed, and cells were exposed 
Scheme 1  Tetrahydroacridine derivatives 1a–1i 
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to the 100 µL of the compound solutions over a range of 
concentrations (final DMSO concentration was below 0.2%) 
or nothing but culture medium (blank control). Pure DMSO 
was used as a positive control. After 24 h of incubation with 
the compound solutions, medium was removed and 50 µL of 
the MTT solution was added to each well and incubated in 
the dark for additional 2 h at 37 °C. Then the MTT solution 
was carefully removed and 100 µL of DMSO was added. 
Plates were incubated for 10 min at room temperature. 
Finally, 5 µL of Sorensen Buffer was added to each well. 
Plate was swayed, and the absorbance was measured by 
using microplate reader (Synergy H1, BioTek, Winooski, 
VT, USA) at a wavelength of 570 nm. The cell viability was 
expressed as a percentage of the control values (blank). The 
experiments were done in triplicate [37].
Colony forming assay
The A549 or HT-29 cells were seeded in 6-well plates (1000 
cells/well). After 24 h, solutions of the test compounds at the 
concentrations of  2xIC50,  IC50, 1/2IC50 were added. The cells 
were incubated for a further 24 h, after which the culture 
medium was changed. The cells were then cultured until 
clear colonies were formed. For the staining of cells, a 5% 
Giemsa solution (Sigma Aldrich) was prepared. After the 
incubation, the culture medium was gently removed from 
each well. The plates were placed on ice. Each well was 
rinsed twice with cold PBS (1 mL). The cells were fixed 
with cold methanol (1 mL) for 20 min. The methanol (Serva) 
was removed, and then the fixed colonies were stained with 
5% Giemsa for 10 min at room temperature. After the incu-
bation, the Giemsa solution was removed. The colonies were 
rinsed with distilled water to remove the excess of the dye. 
Plates were left to dry and then colonies in each well were 
photographed under microscope and calculated. The colony 
is defined to consist of at least 50 cells. Each experiment was 
repeated three times in triplicate. Mean number of colony 
numbers in control wells were expressed as 100%. Number 
of colonies in experimental wells were expressed as percent 
of control number. Results were presented as the mean ± SD 
of three separate experiments [38].
Cell cycle analysis
A549 or HT-29 cells were seeded on 6-well plates at the 
density of 2.5 × 105 cells/well and incubated for 24 h. Then, 
compounds were added into the wells and cells were further 
incubated for 24 h. After incubation, monolayer and super-
natant cells were harvested and washed in PBS. Then, cells 
were centrifuged (monolayer—1200 rpm for 10 min, super-
natant 3500 rpm for 10 min) and fixed in cold 70% ethanol. 
Pellets were kept at 4 °C for at least 2 h. Prior to analysis, 
cells were centrifuged and re-suspended in RNAsi (type 1-A; 
Sigma Aldrich)—PBS working solution (200 µg/mL). Sam-
ples were incubated at 37 °C for 10 min. At the end, 3 µL of 
2 mg/mL propidium iodide (PI) (Sigma Aldrich) solution 
was added to each sample. Samples were kept in the dark 
prior to analysis. Analysis was performed on BD Accuri C6 
Flow Cytometry (Becton–Dickinson). Etoposide (Calbio-
chem) was used as a reference drug. Experiments were done 
in triplicates [39].
Apoptosis assay by annexin‑V/PI double staining
A549 or HT-29 cells were seeded on 6-well plates at the den-
sity of 2 × 105 cells/well and incubated for 24 h. Compounds 
were added to the cells and further incubated for 24 h. After 
treatment, monolayer and supernatant cells were harvested, 
washed with PBS and centrifuged (monolayer at 1200 rpm 
for 10 min, supernatant at 3500 rpm for 10 min). Then, cells 
were re-suspended in binding buffer and stained with 2 µL of 
Annexin-V and 2 µk of PI (ANNEXIN-V—FITC Apoptosis 
Detection Kit, Immunostep) in the dark for 10 min at room 
temperature. Cells were analysed by BD Accuri C6 Flow 
Cytometry (Becton–Dickinson). Etoposide (Calbiochem) 
was used as a reference drug. Experiments were done in 
triplicates [39].
Hyaluronidase inhibition assay
All compounds were tested in a hyaluronidase inhibition 
test in order to determine their anti-inflammatory proper-
ties. The hyaluronidase inhibition study was carried out by 
turbidimetric method modified to the 96-well plates and 
previously described by Michel et al. [40]. Compound solu-
tions were prepared freshly before the assay. The protocol 
started by adding 20 µL of the compound solution in mono-
sodium phosphate buffer (pH 7.0) and 40 µL of hyaluroni-
dase solution (22.55 U/mL, hyaluronidase from bovine testes 
Type I-S, Sigma Aldrich) to the wells of 96-well microtiter 
plates. The solutions were kept in the dark for 10 min at 
the temperature 37 °C. After incubation, 40 µL of hyalu-
ronic acid solution (0.03%, Sigma Aldrich) in monosodium 
phosphate buffer (pH 5.35) was added to the wells. Then 
the mixture was incubated in the dark for 45 min at 37 °C. 
Finally, 300 µL of bovine serum albumin (0.1%, Serva) in 
sodium acetate buffer (pH 3.75) was added to the wells. The 
final incubation was carried out at the room temperature for 
10 min. The changes in turbidity were measured at 600 nm 
by a microplate reader (BioTek, Winooski, VT, USA). The 
assay was run in three experiments in triplicate in order to 
calculate  IC50 values. Heparin (WZF, Polfa Warsaw) was a 
positive control. The inhibitory activity of the tested com-
pounds was calculated as inhibition percentage (% inhibi-
tion) of hyaluronidase according to the equation:
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where AHA—absorbance of solution without the enzyme 
(positive control), AHYAL—absorbance of solution without 
the tested compound (negative control), AAN—absorbance 
of solution with the tested compound.
Cytoprotection against oxidative stress
The cytoprotective properties of novel compounds against 
oxidative stress were measured in three experiments. In 
the first experiment, hydrogen peroxide  (H2O2) was used 
to generate exogenous free radicals. Cells were incubated 
with compounds in the concentrations of  IC50 (and lower) 
for 24 h before the addition of  H2O2 (100 µM). Then,  H2O2 
was added and the incubation in the presence of compounds 
lasted 24 h. In the second and third experiment, combination 
of rotenone (30 µM) (Sigma Aldrich) with oligomycin A 
(10 µM) (Sigma Aldrich) was used to induce mitochondrial 
reactive oxygen species (ROS). In the second experiment 
(pre-incubation), cells were incubated with compounds for 
24 h before the addition of rotenone with oligomycin A. 
Then, the toxic agents were added and the cell incubation in 
the presence of compounds was maintained for additional 
24 h. In the third experiment (co-incubation), compounds 
and the combination of rotenone with oligomycin A were 
added at the same time and then incubated for 24 h. In each 
experiment, the cell death was evaluated by the MTT assay. 
Data were shown as the percentage of the reduction of MTT 
in regard to non-incubated cells. Trolox (the moiety of anti-
oxidant vitamin E) (Sigma Aldrich) was used as a positive 
control. Each experiment was repeated three times in quad-
ruplicates. Data in the tables were showed as the percentage 
of protection—for example loss of cell viability by 25% in 
the drug-treatment sample, means protection of 50% [41, 
42].
Reactive oxygen species assay
A549 or HT-29 cells were seeded in 6-well plates at the 
density of 2.5 × 105 cells/well and incubated for 24 h. After 
incubation, compounds were added into the wells and fur-
ther incubated for next 24 h.  H2O2 (1 mM) was added at 
22nd h of incubation with compounds.  H2O2 was used as 
a positive control. 30 min before the analysis, DCFH-DA 
(20 µM) was added to the wells. After incubation, cells were 
harvested and washed in PBS. Then, cells were centrifuged 
at 1500 rpm for 10 min. Medium was removed and cells 
were suspended in PBS. Analysis was performed on BD 
Accuri C6 Flow Cytometry (Becton–Dickinson) [39].
% Inhibition = 100 ×
(
1 −
(
AHA − AAN
AHA − AHYAL
))
,
DNA unwinding assay
0.3  µg of supercoiled pUC19 DNA (0.5  µg/µL) (Ther-
mofisher) was mixed with 10 × assay buffer (100  mM 
Tris–HCl (pH 7.9), 10 mM EDTA, 1.5 M NaCl, 1% BSA, 
1 mM spermidine, 50% glycerol) (TopoGen), 2 µL of solu-
tions of compounds in chosen concentrations (except of 
two controls) and water. Human Topoisomerase I (TopoI) 
(4U) (TopoGen) was added to the all samples, except one 
of the controls. Dilution buffer (20  mM  NaH2PO4 (pH 
7.4), 300 mM NaCl) (TopoGen) was added to the control. 
Amsacrine (Cayman) and ethidium bromide (EB) (Serva) 
were used as reference compounds. Final volume per sam-
ple was 20 µL. All reactions were carried out in DNAse-
free microcentrifuge tubes. Mixtures were gently mixed and 
incubated in the water bath for 30 min in 37 °C. Reaction 
was terminated by adding 10% SDS (final concentration 1%) 
and 0.6 mg/mL solution of proteinase K (Serva) (final con-
centration 0.05 mg/mL), which was pre-warmed at 37 °C for 
10 min. 6 × Loading Dye (Thermofisher) was added to each 
sample. Samples were analysed in 0.8% agarose gel in TAE 
(Tris–acetate-EDTA, pH 8.30) buffer at 4 V/cm for 4 h at 
the 20 °C. After analysis, gel was stained in the dark with 
EB solution (0.05 µg/mL) for 15 min, de-stained in water for 
5 min and visualized with UV [43].
Protein extraction and Western Blotting analysis
A549 or HT-29 cells were seeded in 6-well plates at the 
density of 2.5 × 105 cells/well and incubated for 24 h. Then, 
cells were treated with chosen compounds. After 24 h of 
incubation, monolayer and supernatant were harvested and 
washed in cold PBS. Cells were centrifuged—monolayer 
at 1200 rpm for 10 min, supernatant 3500 rpm for 10 min. 
Pellets were dissolved in RIPA Lysis and Extraction buffer 
(Bio-Rad) containing Phosphatase Inhibitor Cocktail 3 
(Sigma Aldrich) and Protease Inhibitor Cocktail (Sigma 
Aldrich). Samples were incubated in ice for 30 min and 
mixed every 10 min. Then, samples were centrifuged at 
12,000 rpm for 25 min. Protein concentration in superna-
tants was measured in triplicate using a Protein Assay (Bio-
Rad). Proteins were separated by SDS–polyacrylamide gel 
electrophoresis. Separating and stacking gels were made of 
different ratios of water, Tris–HCl pH 6.8 and pH 8.8, 10% 
SDS (Sigma Aldrich), Acrylamide/bis-acrylamide (Sigma 
Aldrich), 10% APS (Sigma Aldrich), TEMED (Sigma 
Aldrich). 7.5% gels were prepared for analysis PARP-1, 
whereas 12% gels prepared for γ-H2AX. After separation on 
SDS–polyacrylamide gels, proteins were electroblotted on 
nitrocellulose membrane in Transfer Buffer (Glycine, Tris, 
Methanol). Membranes were washed in TBS/0.1% or 0.05% 
Tween20 solution and blocked in Tris-buffered saline with 
5% of non-fated dried milk for 1 h. Membranes were then 
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incubated overnight with primary antibodies—anti-PARP-1 
(Cell Signaling Technology), anti-γ-H2A.X (Cell Signaling 
Technology), anti-β-actin (Cell Signaling Technology) in 
cold room (6 °C). After incubation, membranes well washed 
with TBS/Tween solution and blocked with and horserad-
ish peroxidase-conjugated secondary antibodies (Bio-Rad) 
for 1 h in cold room. Protein bands were visualized using 
ECL™ Prime Western Blotting Detection Reagents (Sigma 
Aldrich) Healthcare and Carestream Kodak autoradiography 
GBX fixer/replenisher (Sigma Aldrich) with Developer and 
Replenisher (Carestream) in the dark room. Results were 
obtained on Autoradiography Film (Santa Cruz Biotech-
nology). Densitometric analysis was performed by using a 
software program (ImageJ). Results were standardized using 
the signal obtained from β-actin [44].
Statistical analysis
Obtained values were represented as mean ± standard devia-
tion (SD) from experiments. One-way ANOVA with post 
hoc analysis was made using the Stat-Soft STATISTICA 
v.13.1 software.
Results
ADMET Analysis
ADMET analysis informs researchers about safety and prob-
ability of success in the development of novel compounds. 
The values for every compound (1a–1i) are presented in 
Table 1. Following the Rule of five, molecular weight was 
lower than 500, number of hydrogen bond donors (expressed 
as the sum of OHs and NHs) were lower than 5, number of 
hydrogen bond acceptors (expressed as the sum of Ns and 
Os) were lower than 10, number of rotatable bonds were 
lower than 10 and an octanol–water partition coefficient log 
P not greater than 5. Almost all compounds did not violate 
Lipinski’s Rule of five, however, 1e–1i had log P slightly 
higher than 5. Other parameters were not violated. The 
Rule of five got its name from the cut-offs of the parameters 
which are close to 5 or multiple of 5 [45–48]. Drugs, which 
violate the Rule, have poor absorption or permeation after 
oral intake. However, some drugs lie outside the parameters 
of the Rule, for example antibiotics, antifungals, vitamins 
and cardiac glycosides. It may be due to their structural fea-
tures which allow drugs to act as substrates for transporters.
The blood–brain barrier (BBB) separates blood circula-
tion and cerebrospinal fluid in the central nervous system. 
By prediction BBB penetration, researchers may find out 
whether compounds pass across the barriers. All of novel 
compounds have log BBB not lower than − 1 and higher 
than 0.3 (0.48–0.59), which show good brain penetrations 
profiles. The iodine in para position and longer carbon chain 
improved BBB permeability [47]. TPSA is the topological 
polar surface area which derived only from polar fragments 
with nitrogen and oxygen. Low topological polar surface 
area (< 75 Å2) may indicate an increase in in vivo toxic-
ity. Moreover, the relationship between clog P and TPSA 
is observed. Compounds with values of clog P < 3 and 
TPSA > 75 Å2 are considered to be non-toxic [49, 50]. All 
Table 1  ADMET prediction values for novel compounds 1a–1i 
Parameters: Log P—an octanol–water partition coefficient; TPSA (Å2)—topological polar surface; Log BB—Blood–Brain Barrier Penetration 
log([Brain]/[Blood])); P-gp—P-glycoprotein; hERG—the human Ether-a-go-go-Related Gene; %PPB—plasma protein binding; Log KaHSA—the 
human serum albumin affinity constant; Vd - the distribution of compounds between plasma and body tissue
1a 1b 1c 1d 1e 1f 1g 1h 1i Tacrine
Molecular weight 471.33 485.36 499.39 471.33 485.36 499.39 471.33 485.36 499.39 200.28
No. of H-bond donors 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00
No. of H-bond acceptor 4.00 4.00 4.00 4.00 4.00 4.00 4.00 4.00 4.00 2.00
No. of rotatable bonds 5.00 6.00 7.00 5.00 6.00 7.00 5.00 6.00 7.00 0.00
Log P 4.79 5.02 5.01 5 5.23 5.21 5.42 5.67 5.66 2.60
TPSA (Å2) 54.02 54.02 54.02 54.02 54.02 54.02 54.02 54.02 54.02 38.38
Log BB 0.48 0.47 0.55 0.55 0.53 0.59 0.55 0.52 0.58 0.21
Probability of positive Ames test 0.72 0.61 0.68 0.72 0.61 0.68 0.72 0.61 0.68 0.77
P-gp inhibitor probability 0.56 0.68 0.60 0.56 0.68 0.60 0.56 0.68 0.60 0.16
P-gp substrate probability 0.43 0.54 0.68 0.43 0.54 0.68 0.43 0.54 0.68 0.12
hERG Inhibitor (Ki < 10 µM) probability 0.56 0.51 0.56 0.56 0.51 0.56 0.56 0.51 0.56 0.10
%PPB 96.67 97.08 97.31 96.67 97.08 97.31 96.67 97.08 97.31 76.27
Log KaHSA 5.15 5.15 4.90 5.15 5.15 4.90 5.15 5.15 4.90 3.73
Vd (L/kg) 8.06 8.40 9.50 11.06 11.16 12.63 11.39 11.49 13.01 5.06
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of our novel compounds have TPSA slightly below 75 Å2 
(54.02 Å2), which may indicate some toxicity.
In order to evaluate potential mutagenicity of our com-
pounds, the Ames test was performed. In general, Ames 
test is a validated in vitro test, in which histidine-dependent 
strain Salmonella typhimurium is exposed to a potential 
mutagen. Frame-shift mutation or base-pair substitutions are 
commonly observed. The in vitro Ames test is referred to the 
in silico calculations. Among novel compounds, test showed 
that compounds 1b, 1e, 1h, with three carbons linker, had 
lowest mutagenic potential (Table 1). The length of the car-
bon chain did not influence on mutagenic potential of novel 
compounds [51]. Visualization of genotoxicity is presented 
in Fig. 1.
hERG (human ether-a-go-go-related gene) codes a protein 
which is a subunit of potassium ion channel. Some drugs 
inhibit hERG and can cause arrhythmias associated with 
lengthened QT interval (torsades de pointes and the risk for 
the sadden death). These drugs should be better examined 
for preclinical and clinical cardiovascular safety assessments 
[52]. The model calculates the probability of the new com-
pound being a hERG inhibitor. In that case,  IC50 is lower 
than the cut-off value of 10 µM. The results are presented 
as values: 1—hERG inhibitor, 0—non-inhibitor [53]. All of 
our novel compounds had values in the range of 0.51–0.56. 
Again, compounds 1b, 1e, 1h with three carbons linker were 
the safest ones. The length of the carbon chain did not influ-
ence on interaction with hERG.
P-Glycoprotein (P-gp) is known as a multidrug resistance 
protein 1 (MDR1), belongs to the ATP Binding Cassette 
Superfamily [54]. P-gp is located in the intestinal epithe-
lium, hepatocytes, renal proximal tubular cells, adrenal 
glands and capillary endothelial cells [34, 55]. Most of 
P-gp substrates are hydrophobic, therefore P-gp is called 
‘hydrophobic vacuum cleaner’ and transports substance 
across extra- and intracellular membranes, extrudes com-
pounds (structurally unrelated hydrophobic substances, 
pollutants and drugs) from inside to outside of cells. P-gp 
transport of novel compounds limiting their bioavailability. 
In the ADMET calculation, drugs can be classified as P-gp 
substrate or inhibitor. There is a correlation between P-gp 
overexpression and MDR resistance. P-gp overexpression 
is found in various cancer cells which develop increased 
efflux activity. Unfortunately, many clinically anticancer 
agents (such as etoposide) are substrates of P-gp [56]. P-gp 
substrates have reduced bioavailability after oral adminis-
tration and decreased ability to cross blood–brain barrier. It 
can cause impairment in effective treatment outcomes [54, 
57–59]. Compounds 1a, 1d and 1g had the lowest ability 
to be P-gp inhibitor or substrate. The position of iodine in 
ortho position influenced the interaction with P-gp, whereas 
the length of the carbon chain did not.
The volume of distribution, the distribution of com-
pounds between plasma and body tissue (Vd), the cumulative 
percentage of a compound bound to human plasma proteins 
(%PPB) and the human serum albumin affinity constant (log 
KaHSA) were calculated [34]. The Vd is general calculated 
from measurements of the total concentration of drug in the 
blood compartment after a single intravascular injection. 
Physical properties of the drug influence on Vd values. Acid 
Fig. 1  Visualization of genotoxic properties of compounds 1a–1i. Genotoxic fragments are coloured in red. (Color figure online)
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drugs bind easier to plasma proteins and have smaller Vds 
than basic drugs, which bind more extravascular proteins 
and have larger Vds. Larger Vd indicates extravascular bind-
ing or storage in fat or other tissues. Vd = 5 L—distribution is 
limited to blood; Vd = 10–20 L—drug penetration into extra-
cellular fluids; Vd = 25–35 L—drug penetration into intra-
cellular fluids; Vd = 40 L—placement in all liquids of the 
body; Vd > 100 L—the drug is strongly concentrated in the 
tissues. The iodo position in para position and longer carbon 
chain increased Vd values. All inhibitors, except 1a, 1b and 
1c, had Vd values above 10 L, which indicated penetration of 
the compounds into extracellular fluids. The most important 
aspect of the drug distribution from plasma to target tissue 
is %PPB. Compounds bind to the blood proteins such as 
albumin (acidic drugs—warfarin, phenytoin), globulin α and 
β (vitamins A, D, E, K,  B12, hormones), acid a1-glycopro-
tein, lipoproteins—(drugs with basic character—proprano-
lol, lidocaine). The clinical significance is observed when 
degree of drug binding with protein is greater than 80%. 
Drug binding to protein is inactive pharmacologically; can-
not pass through biological membranes; is not metabolized 
and cannot be excreted. Drugs with high degree of binding 
are for example coumarin derivatives, phenylbutazone, salic-
ylates, sulphonamides or penicillin. Reducing the degree of 
drug binding results in increasing the potency of the drug 
and shortening of drug action time. All novel compounds 
had very high %PPB—between 96 and 97%. These values 
increased within iodine position in the benzene ring. The 
highest %PPB was observed for iodine in para position. The 
human serum albumin affinity constant was also calculated 
for all compounds. The highest affinity had compounds with 
three or four carbons linker [34].
In vitro cytotoxicity of new compounds 
against cancer and non‑cancer cell lines
The tetrahydroacridine derivatives with iodobenzoic acid 
moiety 1a–1i were tested in vitro by MTT assay against 
two human cancer cell lines—lung adenocarcinoma A549 
and colorectal adenocarcinoma HT-29; and one human 
non-cancer cell line—umbilical vein EA.hy926. Concen-
tration–response analysis was used to determine  IC50 val-
ues. The results are shown in Table 2 and Fig. 2. Widely 
used clinical chemotherapeutic agents— etoposide and 
5-FU were used as positive controls. Etoposide is used to 
treat lung cancer, whereas 5-FU is used in the treatment 
of colorectal cancer. All tested tetrahydroacridine deriva-
tives showed cytotoxicity activity with the  IC50 values in 
the range from 59.12 µM to 5.90 µM against cancer cell 
lines. Controls compounds possessed lower cytotoxicity 
activity than tested derivatives—etoposide  IC50 451.47 µM, 
5-fluorouracil  IC50 1626.85 µM. For A549 cell line,  IC50 
values were higher than for HT-29 cells, which indicated 
that colorectal adenocarcinoma cells were more sensitive 
to tetrahydroacridine derivatives than lung adenocarcinoma 
cells. 1i  (IC50 14.87 µM against A549 and 5.90 µM against 
HT-29) was the most cytotoxic compound versus lung and 
colorectal adenocarcinoma cells. Compounds were divided 
into three groups dependently on the iodine position. 1a–c—
iodine in ortho position, 1d–f—iodine in meta position and 
1g–i—iodine in para position. Against lung and colorectal 
cancer cells, the structure–activity relationship showed that 
longer carbon linker much increased cytotoxic activity. All 
group of para position compounds had the strongest cyto-
toxic effect. The position of iodine in the substituent in the 
Table 2  In vitro cytotoxic activity of compounds 1a–1i and reference compounds on two cancer cell lines (A549 and HT-29) and one non-
cancer cell line (EA.hy926)
All values are presented as the mean ± SD;  IC50, 50% inhibition of the cell viability. Statistical significance was assessed using one-way ANOVA 
analysis was performed
*p < 0.05; **p < 0.01 was considered as significantly different between cancer and non-cancer cell line
Compound Moiety Number of 
carbons
IC50 µM ± SD against A549 IC50 µM ± SD against 
HT-29
IC50 µM ± SD 
against 
EA.hy926
1a 2-Iodobenzoic acid 2 35.96 ± 1.74 17.32 ± 1.22 –
1b 2-Iodobenzoic acid 3 32.52 ± 2.25** 16.08 ± 1.55* 22.42 ± 2.30
1c 2-Iodobenzoic acid 4 59.12 ± 5.86** 13.58 ± 1.39 14.32 ± 1.65
1d 3-Iodobenzoic acid 2 41.16 ± 1.27 7.62 ± 0.19 –
1e 3-Iodobenzoic acid 3 23.49 ± 2.60** 11.03 ± 0.59 11.72 ± 0.62
1f 3-Iodobenzoic acid 4 26.43 ± 2.45** 8.52 ± 0.10** 12.36 ± 1.31
1g 4-Iodobenzoic acid 2 20.79 ± 1.58 8.16 ± 0.44 –
1h 4-Iodobenzoic acid 3 21.36 ± 1.54 9.40 ± 1.65 –
1i 4-Iodobenzoic acid 4 14.87 ± 1.06* 5.90 ± 0.42** 11.30 ± 0.89
Etoposide 451.47 ± 18.27** 155.19 ± 9.81
5-Fluorouracil 1626.85 ± 49.26  > 1800 µM
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Fig. 2  Effect of selected 
compounds on the viability of 
A549 cells, HT-29 cells and 
EA.hy926 cells. Statistical 
significance was assessed using 
one-way ANOVA with a post 
hoc analysis was performed. 
***p < 0.001, **p < 0.01, 
*p < 0.05 was considered as sig-
nificantly different in compari-
son to non-treated control
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para position and 4 carbon linkers most strongly enhanced 
the cytotoxic effect, what was observed for  IC50 values 
for compound 1i. Compounds with the highest cytotoxic-
ity and longer linker (3 or 4 carbons) were chosen for next 
biological tests. Since, the injury of endothelium is one of 
the side effects during chemotherapy, the most active com-
pounds 1b, 1e, 1i towards A549 cell line and the most active 
compounds 1c, 1f, 1i against HT-29 cells were chosen to 
determine their cytotoxicity against normal endothelial cell 
line—EA.hy926. 1c, 1f, 1i presented slightly lower cytotox-
icity effects towards EA.hy926 cells compared to colorectal 
cancer cells (1c  IC50 13.58 µM, 14.32 µM—no statistically 
significant; 1f  IC50 8.52 µM, 12.36 µM statistically signifi-
cant; 1i  IC50 5.90 µM, 11.30 µM statistically significant—
against HT-29 and EA.hy926, respectively). Whereas the 
most toxic compounds 1b, 1e, 1i presented higher toxicity 
for EA.hy926 cells compared to A549 lung cancer cells (1b 
 IC50 32.52 µM, 22.42 µM; 1f  IC50 23.49 µM, 11.72 µM; 1i 
14.87 µM, 11.30 µM—against A549 and EA.hy926 cells, 
respectively). These results suggested that compounds were 
more toxic towards HT-29 colorectal cancer cells than nor-
mal cells—EA.hy926. On the contrary, etoposide showed 
higher cytotoxic activity towards EA.hy926 cells  (IC50 
155.19 µM) than A549 cells  (IC50 451.47 µM), according 
to the data reported by [9]. Finally, 5-fluorouracil presented 
similar cytotoxicity against HT-29 and EA.hy926 cells.
Colony forming assay
The anticancer properties of novel tetrahydroacridine deriva-
tives were tested in the clonogenic assay. Compounds 1b, 
1e, 1i at their  2xIC50,  IC50 and 1/2IC50 concentrations were 
incubated with A549, whereas compounds 1c, 1f, 1i were 
tested in HT-29 cell line. All compounds decreased A549 
colony growth in a concentration-dependent manner (Fig. 3). 
For A549 cells, compound 1i showed the lowest number of 
colonies (highest cytotoxic effect) at its  2xIC50 (0%),  IC50 
(4.70%) and 1/2IC50 (39.47%) concentrations in comparison 
to the same concentrations of compounds 1b and 1e. The 
results were comparable to the results from MTT assay, 
where compound 1i was the most cytotoxic against A549 
cells. In the test with HT-29 cells, compound 1c was the 
most cytotoxic compound at its  2xIC50 (0%),  IC50 (4.38%) 
and 1/2IC50 (10.06%) concentrations in comparison with 1f 
and 1i (Fig. 4). At the concentration of  2xIC50, no cells of 
A549 and HT-29 made colonies. At this concentration the 
strongest apoptotic effect was observed. The only exception 
was compound 1b, for which at  2xIC50 concentration, cell 
made small number of colonies (3.55% in comparison to the 
control). Higher cytotoxic effect was observed for HT-29 
cells than for A549 cells, similar like in the MTT assay.
Cell cycle arrest analysis
The ability of tetrahydroacridine derivatives to impair cell 
proliferation could depend on the block of cell cycle pro-
gression and/or on the induction of apoptosis. To clarify the 
mechanisms of action of these compounds, a flow cytometric 
analysis of cell cycle distribution of A549 and HT-29 cells 
after incubation with our derivatives was performed. Date 
were analysed by FCS Express 4 Flow Cytometry Software. 
Compounds 1b, 1e, 1i at their  IC50 and 1/2IC50 concentra-
tions were chosen to evaluate cell cycle arrest in A549 cell 
line, whereas compounds 1c, 1f, 1i were tested in HT-29 
cell line. Etoposide was used as a reference compound at 
the concentration of 10 µM. Compounds 1b, 1e, 1i induced 
Fig. 3  a Representative colony forming assay of A549 cell line. b 
Number of colonies expressed as percent of control number. Statisti-
cal significance was assessed using one-way ANOVA with a post hoc 
analysis was performed. ***p < 0.001, **p < 0.01, was considered as 
significantly different in comparison to non-treated control
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a significant accumulation of cells G0/G1 phase in com-
parison to control, causing a decrease in S phase cells in 
concentration-dependent manner (Fig. 5) Phase G0/G1 accu-
mulation was induced by all compounds in comparison to 
control. The highest values were observed for 1i (14.87 µM 
76.88%, 7.44 µM 75.93%, control cells 51.74%) (Fig. 6). 
Results were in agreement with those obtained from MTT 
test, where, 1i was the most cytotoxic compound for A549 
cells. Results obtained in HT-29 cells, confirmed that novel 
tetrahydroacridine derivatives induced an accumulation of 
G0/G1 phase cells. However, this effect was smaller than 
that observed in A549 cells. Among compounds, 1c, 1f, 1i—
compound 1c was the most effective (13.58 µM 45.59%, 
6.79 µM 43.75%, non-treated cells 32.23%) (Fig. 7). Etopo-
side (10 µM) induced a G2/M accumulation in both cell 
lines (66.02% accumulation of A549 cells and 73.84%. in 
HT-29 cells).
Apoptosis assay by annexin‑V/PI double staining
Apoptosis is a process of programmed cell death, which 
is necessary to maintain proper homeostasis. Physiologi-
cal apoptosis is responsible for controlling cell numbers, 
morphology of organs and tissue or removal of injured and 
mutated cells. Pathological apoptosis leads to cancers (and 
further to resistance of chemotherapy), neurodegenerative 
and hyperproliferative disorders [60–62]. Important goal 
of anticancer drugs is to induce apoptosis in tumour cells. 
Annexin-V/PI double-staining assay was performed to inves-
tigate whether our novel tetrahydroacridine derivatives were 
able to induce apoptosis [39, 63]. Results were analysed 
by using flow cytometry. Compounds 1b, 1e, 1i at their 
 2xIC50 and  IC50 concentrations were chosen to inducement 
apoptosis in A549 cell line, whereas compounds 1c, 1f, 1i 
were tested in HT-29 cell line. All compounds induced apop-
totic effect in a concentration-dependent manner. In control 
of A549 cells, the mean percentage of total apoptotic cells 
was 7.80%. Compound 1i caused the strongest apoptotic 
effect among compounds tested in A549 cells. After treat-
ment with 1i, at the concentration of 29.74 µM, apoptotic 
cells were 71.98%. For the concentration of 14.87 µM, 
apoptotic cells were 18.79%. Higher apoptotic effect was 
observed for double concentration of  IC50. Compounds 1e 
and 1b also induced a high level of apoptosis at  2xIC50 (by 
44.96% and 45.31%, respectively). Etoposide at the con-
centration of 75 µM—caused total apoptosis at the level 
of 43.46% (Fig. 8). In Fig. 9, plots were divided into four 
quadrants. Each quadrant represents difference type of cells: 
living cells (annexin-V−/PI−, lower left quadrant, LL), early 
apoptotic cells (annexin-V+/PI−, lower right quadrant, LR), 
late apoptotic cells (annexin-V+/PI+, upper right quadrant, 
UR). Among all compounds tested, in HT-29 cell line, total 
apoptotic cells for control were 8.62%. For HT-29 cells, 
compound 1i induced the strongest apoptotic effect. At the 
concentration of 11.80 µM, apoptotic cells were 24.10%. 
At the  IC50 concentration—5.90 µM, apoptotic cells were 
11.80%. However, slightly higher apoptotic effect at  IC50 
was observed for 1c—12.96%. Compound 1i caused higher 
apoptosis in A549 cells than in HT-29 cells. Etoposide at 
the concentration of 25 µM, caused a total apoptotic effect 
by 18.18% (Fig. 8).
DNA unwinding assay
Intercalation of molecules into DNA has been studied 
for many years in order to study novel drugs and gene 
Fig. 4  a Representative colony forming assay of HT-29 cell line. b 
Number of colonies expressed as percent of control number. Statisti-
cal significance was assessed using one-way ANOVA with a post hoc 
analysis was performed. ***p < 0.001, **p < 0.01, was considered as 
significantly different in comparison to non-treated control
134 Molecular and Cellular Biochemistry (2019) 460:123–150
1 3
expression. Intercalator has polycyclic, aromatic struc-
ture, which can insert between bases of the double-helical 
DNA. Acridine and its derivatives are well-known inter-
calators, which binds reversibly to DNA, but usually not 
covalently. Intercalation of acridines is possible due to the 
cationic ionization and molecular planarity. Compounds, 
which intercalate into DNA, lead to local unwinding of 
the DNA and decrease in the twist of DNA. In the pres-
ence of topoisomerase, DNA is nicked and rejoined, which 
results in its relaxation. Removal of the enzyme and tested 
compound leads to conversion relaxed DNA to supercoiled 
DNA. This formation of supercoiled DNA is an indication 
that compound is an intercalator [43].
The ability of compound to bind into DNA, which leads 
to unwinding of the DNA, was determined in DNA unwind-
ing assay catalyzed by human Topoisomerase I. It was 
checked, whether additional moiety influence on intercala-
tion process. Compounds 1b, 1c, 1e, 1f, 1i were tested in 
every three concentrations: 100 µM,  IC50 of A549,  IC50 of 
HT-29. In the agarose gel, depending on shape, supercoiled 
plasmid DNA (S) migrated further, whereas relaxed DNA 
(R) moved shorter distance. EB was not added to the aga-
rose gel. In Fig. 10 and 11, lane 2 shows that supercoiled 
pUC19 DNA was relaxed by the TopoI during incubation 
without any compound. If compound is not an intercalator 
relaxed plasmid is also a product of reaction. Amsacrine, an 
Fig. 5  Percentage of cell cycle 
distribution after 24 h treatment 
of A549 cells with compounds 
1b, 1e, 1i at their  IC50 and 
1/2IC50 concentrations. Percent-
age of cell cycle distribution 
after 24 h treatment of HT-29 
cells with compounds 1c, 1e, 1i 
at their  IC50 and 1/2IC50 concen-
trations. Etoposide was used as 
a reference compound. Experi-
ment was repeated three times. 
Data were presented as the 
mean ± SD. One-way ANOVA 
analysis with post hoc analysis 
was performed. ***p < 0.001, 
**p < 0.01, *p < 0.05 was con-
sidered as significantly different 
in comparison to non-treated 
control
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Fig. 6  A549 cells were treated with the most active compound 1i at its  IC50 and 1/2IC50 concentrations for 24 h. Etoposide (10 µM) was used as a 
reference compound. Analysis of DNA content was performed by using flow cytometry after PI staining
Fig. 7  HT-29 cells were treated with the most active compound 1c at its  IC50 and 1/2IC50 concentrations for 24 h. Etoposide (10 µM) was used as 
a reference compound. Analysis of DNA content was performed by using flow cytometry after PI staining
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inhibitor of human topoisomerase II, and EB, only an inter-
calator, were used as reference compounds. Results showed, 
that amsacrine (100 µM) was stronger intercalator than EB 
(100 µM). 1b, 1c, 1e, 1f at the concentration of 100 µM, 
had bands at the same level as EB. Only 1i, which was the 
strongest cytotoxic compound in the MTT assay, did not 
have any bands at supercoiled level. Among all compounds, 
the compound 1c had the best intercalative potential at con-
centrations of 100 µM and 59.12 µM. Results showed, that 
four from five tetrahydroacridine derivatives could interca-
late into DNA and induced supercoiled form of DNA.
Western blotting studies of the expression 
of PARP‑1 and γ‑H2AX
The induction of apoptosis by tetrahydroacridine deriva-
tives was also investigated through the analysis of poly(ADP 
Ribose) polymerase-1 (PARP-1) cleavage, which is con-
sidered as a hallmark of apoptosis. PARP-1 is a 116 kDa 
protein, which has a wide range of physiological and path-
ological functions. PARP-1 detects and repairs damage 
DNA by binding to strand breaks, initiating base excision 
repair and nucleotide excision repair [64]. One of the cru-
cial signalling pathways involved in apoptosis is the activa-
tion of caspases. During apoptotic process, caspases cleave 
several crucial proteins, which regulate cellular function 
and survival. PARP-1 is one of the substrates of caspases. 
PARP-1 is a target for cleavage by caspase-3 (which also 
cleaves PARP-1 in neurological diseases) and caspase-7. 
Caspases cleave PARP-1 between Asp214 and Gly215 resi-
dues in order to produce 89 kDa and 24 kDa fragments [65, 
66], 89 kDa fragment contains auto-modification domain 
(AMD), and its catalytic domain reduces DNA binding abil-
ity (in non-cleaved PARP AMD induces the recruitment of 
Fig. 8  Cytofluorimetric analysis of apoptosis in A549 and HT-29 
cells after treatment with chosen compounds 1b, 1e, 1i (A549 cells) 
and 1c, 1f, 1i (HT-29 cells) after 24 h of incubation. Data were pre-
sented as the mean ± SD and expressed as percentage of total apopto-
sis. Experiment was repeated three times. One-way ANOVA analysis 
with post hoc analysis was performed. ***p < 0.001, **p < 0.01 were 
considered as significant in comparison to non-treated control
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Fig. 9  A549 cells and HT-29 were treated with the most active compound 1i at its  2xIC50 and  IC50 concentrations for 24 h. Etoposide was used 
as a reference compound
Fig. 10  Lane 1—supercoiled pUC19 DNA; lane 2—pUC19 
DNA + TopoI—resulted in relaxation of plasmid, lane 3—
pUC19 DNA + TopoI + amsacrine (100  µM); lane 4—
pUC19 DNA + TopoI + EB (100  µM); lane 5, 6, 7—pUC19 
DNA + TopoI + 1i 100  µM, 14.87  µM, 5.90  µM, respectively; lane 
8, 9, 10—pUC19 DNA + TopoI + 1f 100  µM, 26.43  µM, 8.52  µM, 
respectively; lane 11, 12, 13—pUC19 DNA + TopoI + 1c 100  µM, 
59.12 µM, 13.58 µM, respectively. Lanes 1–4 are control lanes. Lanes 
5–12 are results lanes of tested compounds. R—relaxed pUC19 
DNA. S—supercoiled pUC19 DNA
Fig. 11  Lane 1—supercoiled pUC19 DNA; lane 2—pUC19 
DNA + TopoI resulted in relaxation of the plasmid, lane 
3—pUC19 DNA + TopoI + amsacrine (100  µM); lane 4—
pUC19 DNA + TopoI + EB (100  µM); lane 5, 6, 7—pUC19 
DNA + TopoI + 1e 100  µM, 23.49  µM, 11.03  µM, respectively; lane 
8, 9, 10—pUC19 DNA + TopoI + 1b 100 µM, 32.52 µM, 16.08 µM, 
respectively. Lanes 1–4 are control lanes. Lanes 5–10 are results 
lanes of tested compounds. R—relaxed pUC19 DNA. S—supercoiled 
pUC19 DNA
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DNA repairing enzymes) and is released from nucleus into 
cytosol. 24 kDa fragment with two zinc-finger motifs, stays 
inside nucleus where inhibits active PARP-1 and irreversibly 
binds to nicked DNA. Binding to strand breaks blocks DNA 
repair enzymes (active PARP-1 is inhibited), weakens DNA 
repair and preserve ATP pools in cell. When cells has tre-
mendous DNA damage, PARP-1 is over-activated and uses 
a large number of NAD+. This activity leads to necrotic cell 
death [60, 67–69].
Tetrahydroacridine derivatives were tested in inducing 
PARP-1 cleavage. Compounds 1b, 1e, 1i were tested in 
A549 cells, whereas 1c, 1f, 1i were used in HT-29 cells—
all compounds were investigated at their  IC50 and 1/2IC50 
concentrations. Cleaved PARP-1 protein (89  kDa) was 
observed in all samples after treatment of A549 cells. The 
highest effect at its  IC50 of each compound was observed 
after treatment with 1i at 14.87 µM. Compound 1b and 1e 
had comparable apoptotic effect at their  IC50 concentrations 
(23.49 µM, 32.52 µM, respectively). However, the high-
est PARP-1 cleavage was observed for 1/2IC50 (11.75 µM) 
of 1e. In HT-29 cells, induction of PARP-1 cleavage was 
lower than for A549 cells Compound 1c and 1f induced 
lower apoptosis at  IC50 concentrations (13.58 µM, 8.52 µM, 
respectively) than 1i. Similar like A549 cells, the highest 
PARP-1 cleavage was observed for 1i at the  IC50 concen-
tration (5.90 µM) (Fig. 12). All tested tetrahydroacridine 
derivatives induced PARP-1 cleavage confirming the apop-
tosis induction.
Our results confirmed that novel tetrahydroacridine 
derivatives caused cytotoxicity, inhibited cell cycle pro-
gression in G0/G, induced apoptosis and intercalated to 
DNA. Next analysis was performed to determine molecular 
mechanism of cell death through western blot analysis of 
γ-H2AX expression. It is well known that double-stranded 
breaks (DSBs) of DNA followed by phosphorylation of his-
tone H2AX (γ-H2AX). H2AX belongs to family of H2A 
proteins. Histone proteins H2A, H2B, H3, H4 form a core, 
around which DNA is wrapped to make a nucleosome com-
plex. H2AX is an important element in the repairing pro-
cess of damaged DNA. It connects to damage sites, which 
activates other DNA repairing processes. H2AX protein is 
unique because of its carboxy tail, which comprises serine 
at position 139. Phosphorylation (by kinase ataxia telangi-
ectasia mutated (ATM)) on the 139th serine residue occurs 
Fig. 12  a Western blot analysis of total (116  kDa) and cleaved 
(89 kDa) PARP-1 proteins levels in A549 and HT-29 cells after 24 h. 
Cells were treated with tetrahydroacridine derivatives at  IC50 and 
1/2IC50 concentrations. b Relative densitometric values of cleaved 
PARP-1 proteins levels. Protein quantification was performed by den-
sitometric scanning. Experiment was repeated at least two times. Data 
were normalized using β-actin, indicated as mean ± SD and expressed 
as a percentage of control. One-way ANOVA analysis with post hoc 
analysis was performed. **p < 0.01, *p < 0.05 were considered as sig-
nificant in comparison to non-treated control
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during DNA damage (γ-H2AX) and after repairing, γ-H2AX 
is dephosphorylated. γ-H2AX is studied by many research’s 
teams in the context of cancer treatment. Numerous cyto-
toxic agents, such as camptothecin, cisplatin, doxorubicin, 
etoposide or bleomycin are known as agents which cause 
DNA damage and formation of γ-H2AX [70–72].
In order to test whether novel tetrahydroacridine could 
induce DNA damage which results in phosphorylate H2AX, 
A549 cells were treated with compounds 1b, 1e, 1i, whereas 
HT-29 cells were treated with 1c, 1f, 1i at their  IC50 and 
1/2IC50 concentrations. In A549 cells, γ-H2AX were obtained 
in all samples after treatment with novel compounds. At 
 IC50 concentration, the strongest effect was observed for 1e, 
and slightly lower for 1b. Compound 1i had higher ability 
to damage DNA at 1/2IC50 concentration (7.44 µM) than at 
 IC50 concentration (14.87 µM) (Fig. 13). In HT-29 cells, the 
strongest H2AX phosphorylation was observed after treat-
ment with 1i and 1f. Among compounds, 1c had the low-
est effect on DNA damage. The effect was noticed at  IC50 
(13.58 µM), but not at 1/2IC50 (6.79 µM) (Fig. 13).
In vitro study on cisplatin‑sensitive 
and cisplatin‑resistant 253J B‑V cells
Since chemoresistance is a common feature during cancer 
progression, we would test the cytotoxic ability of our tet-
rahydroacridine derivatives with iodobenzoic acid moiety in 
cisplatin-resistant and non-resistant 253J B-V bladder cancer 
cells. 253J B-V cells were cultured in and exposed to the 
increasing concentration of cisplatin for 12 months. Resist-
ance induction was described in publication by Ciamporcero 
et al. [36]. On the basis of MTT experiments in A549 and 
HT-29 cell lines, the compounds with longer linker (3 or 4 
methylene groups) and highest cytotoxicity of each subgroup 
were chosen for this study. Compounds 1b, 1c, 1e, 1f and 1i 
were tested in the various concentrations  (IC50 of A549,  IC50 
of HT-29, 1/2IC50, 1/4IC50). Effect was measured after 24 h, 
48 h and 72 h of incubation with compounds (Fig. 14). For 
sensitive and resistant cell lines, a similar cytotoxic effect 
was observed for each compound. The cytotoxicity increased 
over the time. One-way ANOVA analysis demonstrated that 
there were no significant differences of cytotoxicity between 
Fig. 13  a Western blot analysis of γ-H2AX (17  kDa) protein levels 
in A549 and HT-29 cells after 24 h. Cells were treated with tetrahy-
droacridine derivatives at  IC50 and 1/2IC50 concentrations. b Relative 
densitometric values of γ-H2AX proteins levels. Protein quantifi-
cation was performed by densitometric scanning. Experiment was 
repeated at least two times. Data were normalized using β-actin, 
indicated as mean ± SD and expressed as a percentage of control. 
One-way ANOVA analysis with post hoc analysis was performed. 
***p < 0.001, *p < 0.05 were considered as significant in comparison 
to non-treated control
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Fig. 14  In vitro cytotoxic effect 
of tetrahydroacridine derivatives 
on cisplatin-resistant and non-
resistant 253J B-V cells after 
24 h, 48 h and 72 h of incuba-
tion. Experiments were done in 
quadruplicates and repeated two 
times. Statistical significance 
was assessed using one-way 
ANOVA analysis was per-
formed. *p < 0.05, **p < 0.01 
was considered as significantly 
different between viability of 
resistant and non-resistant cells
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sensitive and resistant cells for most of the concentrations 
of compounds. However, for 1b, 1c, 1f differences were 
noticed after 24 h, 48 h or 72 h of incubation. It turned out, 
that resistant cells were more sensitive to the compounds 
1b (after 48 h at the concentrations of 16.08 and 8.04 µM; 
72 h at the concentration of 4.02 µM), 1c (after 72 h at the 
concentration of 6.79 µM), and to the 1f (after 24 h and 48 h 
at the concentrations of 8.52 and 4.26 µM; after 72 h at the 
concentration of 8.52 µM) than non-resistant cells (Fig. 14). 
Taken together these results demonstrated that compounds 
displayed a strong cytotoxic activity in both sensitive and 
cisplatin-resistant cell lines. Acting against chemoresistance 
was observed mostly for compound 1f, where this effect was 
observed for two concentrations after 24 h, 48 h and 72 h 
of observation.
In vitro study on hyaluronidase activity
Inflammation is a biological response to aggressive agents 
or stimuli (pathogens, damaged cells, mechanical injury), 
involving immune and local vascular systems. Inflamma-
tion is controlled by anti-inflammatory mediators such 
as cytokines, chemokines and cellular enzymes (among 
them—hyaluronidase). Hyaluronidase is an enzyme, which 
depolymerises hyaluronan (part of extracellular matrix), 
its activity is increased during inflammation therefore the 
integrity of tissue is weakened during the inflammatory 
process. Chronic inflammation is commonly associated 
with the development of several diseases, such as Alzhei-
mer’s disease, rheumatoid arthritis or cancers. [40, 73–76].
In the present study, the hyaluronidase inhibitory activ-
ity of novel compounds was determined by spectropho-
tometric assay. The  IC50 values of tested compounds and 
the positive control, heparin, are presented in Table 3. All 
Fig. 14  (continued)
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compounds presented good inhibitory activity in the range 
of  IC50 values between 191.17 µM and 383.73 µM. The 
iodine substitution in para position enhanced inhibitory 
activity, as well as shorter carbon linker. The best com-
pound was 1g with 191.17 µM  IC50, when heparin—had 
56.41 µM  IC50. It can be concluded that tetrahydroacridine 
derivatives could possess anti-inflammatory activity.
Cytoprotection against oxidative stress
Oxidative stress derives from an imbalance between forma-
tion and neutralization of ROS. It causes excessive oxidative 
damage to DNA, proteins and further to cells and tissues. 
These changes induce inflammatory diseases, cardiovascu-
lar diseases, aging and cancers. Drugs, which could have 
additionally anti-inflammatory and antioxidant properties, 
are appreciated as anticancer agents [77, 78]. In our study, 
we checked whether novel compounds possesses antioxi-
dant properties (due to the benzoic acid moiety), which at 
low concentration could reverse side effects of anticancer 
therapies.
The cytoprotective properties of tetrahydroacridine deriv-
atives against oxidative stress were measured in three toxic-
ity models. In the first model,  H2O2 was used to generate the 
exogenous free radicals. SH-SY5Y human neuroblastoma 
cells were incubated with compounds 24 h before addition 
of  H2O2. After this time, toxic (100 µM) was added and 
maintained for the next 24 h in the presence of compounds. 
Five compounds were chosen (1b, 1c, 1e, 1f, 1i) and tested 
in four concentration: 1b, at the concentrations of 65.04 µM, 
32.52 µM  (IC50 of A549), 16.26 µM and 1 µM; 1c, at the 
concentrations of 27.16 µM, 13.58 µM  (IC50 of HT-29), 
6.79 µM and 1 µM; 1e, at the concentrations of 46.98 µM, 
23.49 µM  (IC50 of A549), 11.75 µM and 1 µM; 1f at the con-
centrations of 17.04 µM, 8.52 µM  (IC50 of HT-29), 4.26 µM 
and 1 µM; 1i at the concentrations of 29.74 µM, 14.87 µM 
 (IC50 of A549), 5.90 µM  (IC50 of HT-29) and 1 µM. Cell 
treated with  H2O2 only (in the absence of novel compounds), 
showed a viability of 82.74% in comparison to non-treated 
control cells. The antioxidant trolox (6-hydroxy-2,5,7,8-
tetramethylchroman-2-carboxylic acid), at the concentra-
tion of 1 µM, was used as positive control. Cells incubated 
with trolox showed viability of 99.38% and cytoprotection 
of 96.38%. Only compound 1c provided small cytotoxic-
ity (Fig. 15) and had cytoprotective property at concentra-
tions of 13.58 µM, 6.79 µM—28.45%, 89.47%, respectively 
(Table 4). Rest of the compounds, apart from 1i, had cyto-
protection properties only at the concentration of 1 µM (1b, 
1e, 1f—98.40%, 40.67%, 95.35%, respectively), which was 
even higher or slightly lower (for 1e) than that of trolox. 
Almost all results were statistically significant in compari-
son to  H2O2 treated cells (without any other compound) 
(Table 4). Incubation of 1i with toxic stimulus resulted in 
high increase of cytotoxicity, therefore neuroprotection was 
not observed at any dose.
Rotenone with oligomycin A (R/O) were taken to 
induce mitochondrial ROS by blocking of complexes I 
and V of the mitochondrial electron transport chain. It 
causes free radical production and blockade of ATP syn-
thesis [79]. In the pre-incubation experiment, it could 
be assessed whether the compounds have cytoprotective 
properties due to the activation of endogenous antioxidant 
pathways. In the co-incubation could be shown whether 
Table 3  In vitro hyaluronidase inhibitory activity of novel com-
pounds 1a–1i and a positive control, heparin
All values are presented as the mean ± SD;  IC50, 50% inhibition of 
enzyme activity. Statistical significance was assessed using one-way 
ANOVA
***p < 0.001 was considered as significantly different from control 
heparin
Compound HYAL
IC50 ± SD (µM)
1a 233.62 ± 7.90***
1b 232.68 ± 4.87***
1c 243.54 ± 7.95***
1d 299.56 ± 6.30***
1e 230.58 ± 5.64***
1f 383.73 ± 10.18***
1g 191.17 ± 10.78***
1h 200.65 ± 8.36***
1i 233.64 ± 8.98***
Heparin 56.41 ± 0.78
Fig. 15  Protection by 1c against  H2O2 (100 µM) in SH-SY5Y cells. 
Cell viability was evaluated by MTT assay. Trolox was used as 
a reference antioxidant. Data were presented as the mean ± SD. 
One-way ANOVA analysis with post hoc analysis was performed. 
***p < 0.001; *p < 0.05 was considered as significantly different com-
paring with  H2O2-damaged cells without drug incubation
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compounds are free-radical scavengers [42, 80–82]. MTT 
assay was a test of choice, because in this assay mitochon-
drial activity is measured. Live cells can reduce MTT, 
whereas apoptotic or necrotic cells do not carry out this 
chemical modification. It can be determined whether novel 
compound would protect cells from both apoptotic and 
necrotic death resulting from the increase of intracellular 
ROS. In both experiments, trolox was used as a reference 
compound. In the pre-incubation experiment, SH-SY5Y 
cells were incubated with the compounds for 24 h before 
the addition of R/O mixture. After this time, toxic mixture 
was added, and cells were maintained for an additional 
24 h in the presence of the compounds.
In the pre-incubation assay, SH-SY5Y cells were treated 
with compounds (1b, 1c, 1e, 1f, 1i) in the range of con-
centration 1–0.001 µM. Cells exposed to the R/O mixture 
showed viability of 47.39% in the incubation without any 
compound (Table 5). Compounds 1b and 1i did not show 
cytoprotective properties at the chosen concentrations. 
Compound 1c, 1e, 1f showed their action against oxida-
tive stress in the whole range of concentrations (Fig. 16, 
Table 6) and were stronger antioxidants than trolox. 
In the co-incubation assay, compounds and mixture of 
R/O were incubated together for 24 h. Cells exposed to the 
R/O mixture showed viability of 45.92% in the incuba-
tion without any compound. Trolox showed cytoprotective 
Table 4  Cytoprotection (%) in 
the cell line SH-SY5Y against 
 H2O2 (100 µM) at the chosen 
concentrations
One-way ANOVA analysis with post hoc analysis was performed
***p < 0.001; **p < 0.01; *p < 0.05 was considered as significantly different comparing with 
 H2O2-damaged cells without drug incubation
Cells viability (%) ± SD after 24 h of incubation with compound and  H2O2
Compound Concentration (µM)
1b 65.04 32.52 16.26 1
17.21 ± 1.18*** 24.93 ± 3.23*** 64.61 ± 4.88** 99.20 ± 1.67**
1c 27.16 13.58 6.79 1
36.66 ± 5.57** 87.65 ± 6.40 98.18 ± 2.49* 100.83 ± 1.19*
1e 46.98 23.49 11.75 1
17.39 ± 2.15*** 21.78 ± 3.21*** 59.16 ± 6.70* 89.76 ± 8.55
1f 17.04 8.52 4.26 1
23.85 ± 2.08*** 36.99 ± 5.12*** 79.45 ± 9.87 94.34 ± 7.26
1i 29.74 14.87 5.90 1
18.74 ± 1.25*** 20.72 ± 1.45*** 25.95 ± 1.24*** 29.68 ± 3.39***
Trolox 1
99.38 ± 9.81*
Table 5  SH-SY5Y cells 
viability (%) with ± SD of pre-
incubation and co-incubation 
assays against mixture 
of rotenone (30 µM) and 
oligomycin A (10 µM) at the 
chosen concentrations
One-way ANOVA analysis with post-hoc analysis was performed
**p < 0.01, *p < 0.05 was considered as significantly different comparing with R/O cells without drug 
incubation
Compound Concentration Cell viability (%)
1 µM 0.1 µM 0.01 µM 0.001 µM
1b Pre-incubation 34.41 ± 5.19 44.39 ± 5.77 46.92 ± 6.20 48.50 ± 6.87
Co-incubation 37.28 ± 3.50 41.01 ± 6.63 42.54 ± 4.14 45.82 ± 4.69
1c Pre-incubation 65.23 ± 9.74 64.83 ± 5.19 66.88 ± 2.33 64.71 ± 5.67
Co-incubation 39.88 ± 5.68 39.09 ± 5.40 42.34 ± 5.08 44.86 ± 4.82
1e Pre-incubation 60.43 ± 7.22 71.80 ± 9.55* 74.32 ± 2.80* 66.45 ± 5.06
Co-incubation 35.62 ± 1.66* 37.61 ± 3.15 39.82 ± 2.24 43.60 ± 3.44
1f Pre-incubation 63.60 ± 9.26 65.92 ± 7.34 66.15 ± 8.29 77.46 ± 11.20*
Co-incubation 36.35 ± 2.34** 37.60 ± 2.39** 39.53 ± 1.11* 40.19 ± 0.42
1i Pre-incubation 28.96 ± 2.35** 35.63 ± 4.86 39.82 ± 2.63 41.26 ± 4.21
Co-incubation 33.69 ± 2.87* 34.51 ± 3.36* 39.92 ± 2.43 47.53 ± 2.30
Trolox Pre-incubation 47.67 ± 2.46 44.26 ± 3.73 46.38 ± 2.06 47.91 ± 4.48
Co-incubation 49.23 ± 8.49 48.09 ± 8.01 50.34 ± 8.11 50.83 ± 6.98
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properties in whole range of concentration (1 µM, 0.1 µM, 
0.01 µM, 0.001 µM—6.12%, 4.02%, 8.18%, 9.08%, respec-
tively). It turned out that none of the compounds (apart from 
1i at the concentration of 0.001 µM and cytoprotection of 
2.99%) had cytoprotective properties in the whole range 
of concentrations (Fig. 17). Compounds were not able to 
capture free radicals; therefore they cannot be classified as 
free-radical scavengers.
Moreover, we verified whether novel compounds could 
protect A549 and HT-29 cells against stress induced by 
 H2O2. Cellular ROS was detected by measuring DCF fluo-
rescence intensity. A549 and HT-29 cells were treated with 
compounds at  IC50 concentration. Previous study on SH-
SY5Y cell line confirmed, that compounds did not protect 
cells against  H2O2 toxic stimulus, even if they were pre-
incubated with compounds. Only 1c showed cytoprotection 
against  H2O2. ROS level after treatment only with toxic stim-
ulus was increased 1.86- and 1.88-fold (for A549 and HT-29 
cells, respectively) in comparison with non-treated control. 
Even higher ROS level than after treatment only with  H2O2 
was observed for A549 cells after incubation compounds. 
For 1i, 1e, 1b—it was 1.98-fold increase in ROS level 
production. In HT-29 cells, compounds 1c, 1f, 1i caused 
1.83-fold, 1.87-fold and 1.85-fold increase in ROS level. 
It was only slightly lower than for  H2O2 treatment. Results 
showed that compounds did not act again oxidative stress 
in A549 and HT-29 cells. Since cancer cells produce high 
level of ROS (which makes cancer cells more vulnerable 
to the agents that further increase ROS levels), the lack of 
ROS scavenger activity of novel compounds may represent 
an important clue to their use as chemotherapeutic drugs.
Discussion
Cancerous diseases are the third reason of death worldwide. 
Among all cases, the most common cause of death in both 
sexes is lung cancer, when colorectal cancer is the third 
cause of death among other types of cancers [1, 2]. Among 
different groups of drugs used in chemotherapy, acridine 
derivatives, which are tricyclic heterocyclic compounds, 
have been extensively explored as potential therapeutic 
Fig. 16  SH-SY5Y cells viability (%) of pre-incubation assay against 
mixture of rotenone (30 µM) and oligomycin A (10 µM) at the cho-
sen concentrations of compounds 1i, 1b, 1c, 1e, 1f. Trolox was used 
as a reference antioxidant. Data were presented as the mean ± SD. 
One-way ANOVA analysis with post hoc analysis was performed. 
**p < 0.01, *p < 0.05 was considered as significantly different com-
paring with R/O cells without drug incubation
Table 6  Cytoprotection (%) of the compounds 1c, 1e, 1f and trolox in 
the SH-SY5Y cells in the pre-incubation assay with mixture of rote-
none (30 µM) and oligomycin A (10 µM)
Compound Concentration
Cytoprotection
1 µM (%) 0.1 µM (%) 0.01 µM 0.001 µM
1c 33.92 33.15 37.05 32.91
1e 24.79 46.39 51.19 36.22
1f 30.81 35.21 35.65 57.16
Trolox 0.53 – – 0.98
Fig. 17  SH-SY5Y cells viability (%) of co-incubation assay against 
mixture of rotenone (30 µM) and oligomycin A (10 µM) at the chosen 
concentrations of compounds 1f, 1e, 1c, 1b, 1i. Data were presented 
as the mean ± SD. One-way ANOVA analysis with post hoc analysis 
was performed. **p < 0.01, *p < 0.05 was considered as significantly 
different comparing with R/O cells without drug incubation
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agents for the cancer treatment [83]. A basic mechanism 
of acridines is intercalation of DNA in space between base 
pairs due to plate, polycyclic aromatic structure. Overall, 
acridine derivatives have a long history in therapeutics. 
They are used as antibacterial agents (ethacridine lactate—
rivanol) [84] or antimalarial agents (mepacrine) [85]. Luck-
ily, they use in chemotherapy was also confirmed as the drug 
like amsacrine [86]. In order to obtain new derivatives of 
acridine, the amino group is modified, and different moieties 
are added to the structure. These processes lead to mod-
ify efficacy and toxicity of compounds. Novel compounds 
should damage DNA, induce apoptosis or arrest cell cycle in 
cancer cells. Induction of these processes are an important 
factors in effective chemotherapy.
We have synthesized and evaluated novel tetrahydroacri-
dine derivatives with iodobenzoic moiety. Nine compounds 
were divided into three groups and tested against cancer 
cell lines A549 and HT-29 cells, and non-cancer cell line, 
EA.hy926 cells. The overall results showed that all com-
pounds displayed high cytotoxicity activities towards cancer 
cell lines and were more effective than reference compounds. 
Moreover, HT-29 cells were more sensitive to tetrahydroacr-
idine derivatives than A549 cells.
Reference compounds were chosen with justification. 
Recommended regimens for lung cancer include etoposide, 
cisplatin, paclitaxel or vincristine [87]. Moreover, many 
researchers in their work on A549 cell line, use etoposide 
as a positive control [12, 88]. Therefore, it was our justifica-
tion to use etoposide as a reference compound in study. As 
a control for HT-29 cells, 5-fluorouracil was used. 5-fluo-
rouracil is widely used in the treatment of various cancers, 
such as colorectal, breast, head and neck cancers. Among 
mentioned cancers, in colorectal cancer that 5-FU has the 
greatest impact. Against colorectal cancer, 5-FU is also used 
with a combination with other drugs as—FOLFOX (5-FU, 
leucovorin and oxaliplatin), CapeOx (capecitabine and 
oxaliplatin) or FOLFIRI (5-FU, leucovorin and irinotecan) 
[89–91]. Also many researchers in their work on HT-29 cell 
line, use 5-FU as a positive control. All compounds were 
tested for 24-h incubation, therefore also positive controls—
etoposide and 5-fluorouracil were incubated with cells for 
1 day. As it is seen, 5-fluorouracil has very small cytotoxic 
effect on HT-29 cells after 24-h of incubation, which was 
also confirmed in different publications. The highest cyto-
toxic effect on HT-29 cells starts after 5 days of incubation 
[92, 93]. Also 24 h of incubation A549 cells with etoposide 
provides average cytotoxic effect, which increases with time 
of incubation. After 72-h incubation with etoposide, the  IC50 
is in the range of 50 µM [94]–106 µM [95].
Structure–activity relationship presented that the position 
of iodine in the para position and longer linker (3–4 carbon 
atoms) best improved the cytotoxic effect. Among all deriva-
tives, 1i (iodine in the para position and 4 carbon atoms 
linker) was the most toxic towards both cell lines. Effect 
of cytotoxicity on EA.hy926 cells (human umbilical vein 
cells) is interesting issue in chemotherapy. Chemotherapy 
has many side effects. Not only cancer cells are killed, but 
also in normal cells apoptosis is induced. Anticancer agents 
showed their cytotoxic effects towards various non-cancer 
cells. Especially the endothelial damage is observed, which 
leads to many consequences. The damage can be classified 
into groups on the basis on mechanisms—direct endothe-
lial damage, activation of coagulation factors, autonomic 
dysfunction, stimulation of fibroblasts. Damage can further 
lead to many side effects such as Raynaud’s phenomenon, 
cerebrovascular attacks, hypertension, myocardial ischae-
mia and infarction, pulmonary or hepatic veno-occlusive 
disease. Moreover, evaluation of endothelial function may 
be important to identify risk for cardiovascular events in 
patients who receive chemotherapy [96]. Etoposide, which 
is used in the treatment of lung cancer, induced apoptosis 
of non-cancer cells such as epithelial cells and thymo-
cytes [97, 98]. Among agents, which also induce toxicity 
in endothelial cells, are doxorubicin, paclitaxel and bleo-
mycin. The side effects in vivo with clinical impairments 
regards pulmonary fibrosis (by bleomycin), cardiovascular 
alteration (by doxorubicin), renal dysfunction were caused 
by injury of microvascularization. Etoposide and paclitaxel 
are less toxic towards endothelial cells than bleomycin and 
doxorubicin. All agents trigger apoptosis in human umbili-
cal vein endothelial cells by Bcl-2, but not p53 [99]. On the 
other hand, paclitaxel, doxorubicin, etoposide can have an 
impact on anti-angiogenic or anti-vascular effects in vivo 
by inducing apoptosis of the endothelial cells surrounding 
the tumour (at the concentrations less toxic for the cells of 
the other veins and for cancer cells). However, bleomycin 
at its concentration triggers apoptosis of endothelial cells 
close to the level that inducing overall endothelium toxicity. 
Even though, all agents are used in chemotherapy. Moreover, 
better understanding of the mechanism endothelial injury 
caused by chemotherapy, might lead to better prevention 
from the damage [96, 100–102]. The results on non-cancer 
cell line suggested that selected compounds were more toxic 
towards HT-29 colorectal cancer cells than normal cells—
EA.hy926 cell line. When compare results from EA.hy926 
cells and A549 cells cytotoxicity, higher toxic effect was 
observed for endothelial cells. Similar effect was observed 
for etoposide, which was much more toxic on EA.hy926 
cells than on A549 cells. Even though, etoposide and other 
anticancer agents, which are harmful for endothelial cells, 
are used in chemotherapy. But yet, novel tetrahydroacrid-
ine with iodobenzoic acid would be safer for distributing in 
veins and using towards colorectal cancer cells (HT-29) than 
lung cancer cells (A549). Moreover, ADMET prediction 
showed that almost all compounds did not violate Lipins-
ki’s rule, had good pharmacokinetic profiles and would have 
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good oral bioavailability. However, small problems of oral 
absorption might be observed for compounds 1e–1i.
Multidrug resistance appears in tumour cells during 
administration of chemotherapy. It is a major problem dur-
ing treatment, when cancer cells do not react to many drugs, 
such as etoposide, cisplatin, 5-FU. Therefore, successful 
treatment cannot be obtained and many patients die. Drug 
resistance can be attributed to various mechanisms, such 
as alterations in apoptotic pathways, enhanced expression 
of multidrug resistance-associated proteins, altered drug 
metabolism or uptake and overexpression of cytoprotective 
genes [103]. Taken into consideration drug resistance prob-
lem, preliminary test was performed. We tested the cytotoxic 
ability of our tetrahydroacridine derivatives with iodoben-
zoic acid moiety in cisplatin-resistant and non-resistant 253J 
B-V bladder cancer cells. We obtained similar (without sta-
tistical difference) cytotoxic effect for sensitive and resistant 
cell lines for compounds 1e and 1i. For 1b, 1c, 1f difference 
were noticed after 24 h, 48 h or 72 h of incubation, where 
higher cytotoxicity appears in resistant cells than in non-
resistant. However, for 1b and 1c stronger cytotoxic effect 
in resistant cells was observed only in few concentration 
and was not repeated in every time of incubation. There-
fore, taken together these results demonstrated that almost 
all compounds displayed a strong cytotoxic activity in both 
sensitive and cisplatin-resistant cell lines. Acting against 
chemoresistance was observed mostly for compound 1f, 
where higher cytotoxic effect in resistant cells was observed 
for two concentrations after 24 h, 48 h and 72 h of observa-
tion. Compound 1f will be further examined on etoposide-
resistant A549 cells and 5-fluorouracil-resistant HT-29 cells.
Inhibition of A549 and HT-29 proliferation were due to 
the inhibition of the progression cell cycle from G0/G1 to S 
phase. An accumulation in G0/G1 phase after treatment with 
1i was observed in A549 cells, and after treatment of 1c in 
HT-29 cells. The nature of apoptosis and overall apoptosis 
was also determined. After treatment with compounds, late 
stage of apoptotic cells was observed in great amount and 
1i showed the highest level of total apoptosis (71.98% of 
apoptotic cells) at its highest concentration. Diverse effect 
was determined in HT-29 cells: greater part of total apop-
tosis consists of early apoptotic cells. Again, compound 1i 
(at its highest concentration) caused the strongest apoptotic 
effect (24.10%), though it was significantly lower than one 
observed in A549 cells. In the colony forming assay, the 
highest cytotoxic effect (the smallest number of colonies) at 
the concentration of  IC50 was observed for 1i in A549 cells, 
and for 1c in HT-29 cells. These results were comparable 
with results at  IC50 from cell cycle arrest assays, where 1i 
at caused the strongest inhibition of cell cycle in A549, and 
1c in HT-29 cells. Similar effects were observed for com-
parison of colony forming and apoptosis results. The strong-
est apoptotic effect and the lack of colonies were observed 
for  2xIC50 concentration of all compounds, beside 1b. The 
results were comparable for apoptosis and colony forming at 
the  IC50 concentration. At the  IC50 concentration, the highest 
apoptotic effect and the smallest number of colonies were 
observed for 1i in A549 cells, and for 1c in HT-29 cells. Cas-
pases activation is one of the most important signalling path-
ways that is involved in apoptosis—caspases play the key 
role in the initiation and execution of apoptosis. Caspases 
cleave PARP-1 (which is a substrate for caspases) between 
Asp214 and Gly215 residues in order to produce 89 kDa and 
24 kDa fragments. PARP-1 cleavage (observed as 89 kDa) 
confirmed that all compounds activated apoptotic pathway 
due to the caspases activation, because PARP-1 is a substrate 
for caspases 3 and 7. Therefore to test apoptosis pathway, we 
used PARP-1 in our assay. The PARP-1 cleavage in A549 
cells was more evident than in HT-29 cells. Considering  IC50 
concentrations, 1e and 1i caused the highest PARP-1 cleav-
age for A549 cells, whereas for HT-29 cells the strongest 
cleavage was observed for 1i at the  IC50 concentration. DNA 
damage was confirmed in H2AX phosphorylation analysis. 
Consistent results—induction of G1 cell cycle arrest and 
H2AX phosphorylation—were obtained for another group of 
tetrahydroacridine derivatives with fluorobenzoic moieties 
[12, 13]. DNA damage targets two cell cycle checkpoints—
G1/S and G2/M. DNA damage induces program that blocks 
cells at one of these checkpoints until damage is repaired or 
cells are turn into apoptosis [104].
We checked whether addition of benzoic acid derivatives 
to the tetrahydroacridine influence on antioxidant activities 
[32]. Except for three interferences (tangeretin with tamox-
ifen, NAC with doxorubicin and beta-caroten with 5-fluo-
rouracil), many data show the increase in effectiveness as 
well as decrease of side effects of chemotherapeutic drugs 
when administrated with antioxidants [25]. We performed a 
few studies on anti-inflammatory and antioxidant activities 
of novel compound. The inhibition of hyaluronidase activity 
suggested that compounds possess small anti-inflammatory 
properties. Cytoprotection against mitochondrial ROS was 
not observed in the co-incubation assay. On the contrary, 
it turned out that longer cell incubation with low doses of 
drugs (lower than  IC50) might induce endogenous antioxi-
dant pathways after treatment with 1c, 1e, 1f, so these com-
pounds had little cytoprotection activity, and only at doses 
lower than  IC50. Compounds were not able to capture free 
radicals; therefore they cannot be classified as free-radical 
scavengers. In the last study,  IC50 concentration of the drugs 
lead to increase of ROS production in A549 and HT-29 
cells, which can relate to induction of apoptosis in cancer 
cells. To conclude, three compounds at the concentrations 
lower than  IC50 had small cytoprotection activity (which can 
relate to the possibility of decrease of side effects in chemo-
therapy), and at  IC50 concentrations all compounds had no 
protection activity, which may further result in the death of 
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cancer cells. To conclude, iodobenzoic acid has almost no 
impact on antioxidant activity, because antioxidant effect 
was observed at low level.
In summary, among all compounds, 1c and 1i stood out. 
Both compounds have 4-carbons linker, which may contrib-
ute to cytotoxic activity. Even though higher cytotoxicity 
in MTT assay was observed for HT-29 cells than for A549, 
stronger cell cycle arrest, apoptosis, PARP-1 cleavage and 
DNA damage was confirmed for A549 cells. Further study 
will be carried out to determine another protein signalling 
of cell death and to explain their influence on combating of 
chemoresistance.
Acknowledgements Research funded by the grant of the Medical 
University of Lodz Nos. 502-02/3-015-01/502-34-091 and 503/3-015-
01/503-31-002 is gratefully acknowledgement. MTT cytotoxicity study 
was performed at the Animal House of the Faculty of Pharmacy at the 
Medical University of Lodz.
Compliance with ethical standards 
Conflict of interest The authors declare that they have no conflict of 
interests.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creat iveco 
mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
References
 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A 
(2018) Global cancer statistics (2018): GLOBOCAN estimates of 
incidence and mortality worldwide for 36 cancers in 185 coun-
tries. CA A Cancer J Clin 68:394–424. https ://doi.org/10.3322/
caac.21492 
 2. Dhanavel S, Nivethaa EAK, Narayanan V, Stephen A (2017) 
In vitro cytotoxicity study of dual drug loaded chitosan/palla-
dium nanocomposite towards HT-29 cancer cells. Mater Sci Eng 
C 75:1399–1410. https ://doi.org/10.1016/j.msec.2017.03.058
 3. Siahmansouri H, Somi MH, Babaloo Z, Baradaran B, Jadidi-Nia-
ragh F, Atyabi F, Mohammadi H, Ahmadi M, Yousefi M (2016) 
Effects of HMGA2 siRNA and doxorubicin dual delivery by chi-
tosan nanoparticles on cytotoxicity and gene expression of HT-29 
colorectal cancer cell line. J Pharm Pharmacol 68:1119–1130. 
https ://doi.org/10.1111/jphp.12593 
 4. Seyed MA, Jantan I, Bukhari SNA, Vijayaraghavan K (2016) 
A comprehensive review on the chemotherapeutic potential of 
piceatannol for cancer treatment, with mechanistic insights. J 
Agric Food Chem 64:725–737. https ://doi.org/10.1021/acs.
jafc.5b059 93
 5. Li P-L, Zhang X, Wang L-L, Du L-T, Yang Y-M, Li J, Wang C-X 
(2015) microRNA-218 is a prognostic indicator in colorectal can-
cer and enhances 5-fluorouracil-induced apoptosis by targeting 
BIRC5. Carcinogenesis 36:1484–1493. https ://doi.org/10.1093/
carci n/bgv14 5
 6. Pommier Y (2013) Drugging topoisomerases: lessons and chal-
lenges. ACS Chem Biol 8:82–95. https ://doi.org/10.1021/cb300 
648v
 7. Pommier Y, Marchand C (2011) Interfacial inhibitors: targeting 
macromolecular complexes. 11:25. https ://doi.org/10.1038/nrd34 
04
 8. Byun JS, Sohn JM, Leem DG, Park B, Nam JH, Shin DH, Shin 
JS, Kim HJ, Lee K-T, Lee JY (2016) In vitro synergistic antican-
cer activity of the combination of T-type calcium channel blocker 
and chemotherapeutic agent in A549 cells. Bioorg Med Chem 
Lett 26:1073–1079. https ://doi.org/10.1016/j.bmcl.2015.12.010
 9. Mailloux A, Grenet K, Bruneel A, Bénéteau-Burnat B, Vau-
bourdolle M, Baudin B (2001) Anticancer drugs induce 
necrosis of human endothelial cells involving both onco-
sis and apoptosis. Eur J Cell Biol 80:442–449. https ://doi.
org/10.1078/0171-9335-00171 
 10. Demeunynck M (2004) Antitumour acridines. Expert Opin Ther 
Pat 14:55–70. https ://doi.org/10.1517/13543 776.14.1.55
 11. Vispé S, Vandenberghe I, Robin M, Annereau JP, Créancier L, 
Pique V, Galy JP, Kruczynski A, Barret JM, Bailly C (2007) 
Novel tetra-acridine derivatives as dual inhibitors of topoi-
somerase II and the human proteasome. Biochem Pharmacol 
73:1863–1872. https ://doi.org/10.1016/j.bcp.2007.02.016
 12. Szymański P, Olszewska P, Mikiciuk-Olasik E, Różalski A, 
Maszewska A, Markiewicz Ł, Cuchra M, Majsterek I (2017) 
Novel tetrahydroacridine and cyclopentaquinoline derivatives 
with fluorobenzoic acid moiety induce cell cycle arrest and 
apoptosis in lung cancer cells by activation of DNA damage 
signaling. Tumor Biol 39:1–13. https ://doi.org/10.1177/10104 
28317 69501 1
 13. Olszewska P, Mikiciuk-Olasik E, Błaszczak-Świątkiewicz K, 
Szymański J, Szymański P (2014) Novel tetrahydroacridine 
derivatives inhibit human lung adenocarcinoma cell growth 
by inducing G1 phase cell cycle arrest and apoptosis. Biomed 
Pharmacother 68:959–967. https ://doi.org/10.1016/j.bioph 
a.2014.10.018
 14. Oppegard LM, Ougolkov AV, Luchini DN, Schoon RA, 
Goodell JR, Kaur H, Billadeau DD, Ferguson DM, Hiasa H 
(2009) Novel acridine-based compounds that exhibit an anti-
pancreatic cancer activity are catalytic inhibitors of human 
topoisomerase II. Eur J Pharmacol 602:223–229. https ://doi.
org/10.1016/j.ejpha r.2008.11.044
 15. Sondhi SM, Singh J, Rani R, Gupta PP, Agrawal SK, Sax-
ena AK (2010) Synthesis, anti-inflammatory and anticancer 
activity evaluation of some novel acridine derivatives. Eur 
J Med Chem 45:555–563. https ://doi.org/10.1016/j.ejmec 
h.2009.10.042
 16. de Almeida SMV, Lafayette EA, Gomes da Silva LPB, Amorim 
CAdC, de Oliveira TB, Gois Ruiz ALT, de Carvalho JE, de 
Moura RO, Beltrão EIC, de Lima MdCA, de Carvalho Júnior 
LB (2015) Synthesis, DNA binding, and antiproliferative activity 
of novel acridine-thiosemicarbazone derivatives. Int J Mol Sci 
16:13023–13042. https ://doi.org/10.3390/ijms1 60613 023
 17. Kožurková M, Sabolová D, Kristian P (2017) A review on acridi-
nylthioureas and its derivatives: biological and cytotoxic activity. 
J Appl Toxicol 37:1132–1139. https ://doi.org/10.1002/jat.3464
 18. Ferguson LR, Denny WA (2007) Genotoxicity of non-covalent 
interactions: DNA intercalators. Mutat Res/Fund Mol Mech 
Mutagenesis 623:14–23. https ://doi.org/10.1016/j.mrfmm 
m.2007.03.014
 19. Ozben T (2007) Oxidative stress and apoptosis: impact on can-
cer therapy. J Pharm Sci 96:2181–2196. https ://doi.org/10.1002/
jps.20874 
 20. Cadenas E, Davies KJ (2000) Mitochondrial free radical gen-
eration, oxidative stress, and aging. Free Radic Biol Med 
29:222–230
148 Molecular and Cellular Biochemistry (2019) 460:123–150
1 3
 21. Fan C, Chen J, Wang Y, Wong YS, Zhang Y, Zheng W, Cao W, 
Chen T (2013) Selenocystine potentiates cancer cell apoptosis 
induced by 5-fluorouracil by triggering reactive oxygen species-
mediated DNA damage and inactivation of the ERK pathway. 
Free Radic Biol Med 65:305–316. https ://doi.org/10.1016/j.freer 
adbio med.2013.07.002
 22. Moss RW (2006) Should patients undergoing chemotherapy and 
radiotherapy be prescribed antioxidants? Integr Cancer Ther 
5:63–82. https ://doi.org/10.1177/15347 35405 28588 2
 23. Salganik RI (2001) The benefits and hazards of antioxidants: 
controlling apoptosis and other protective mechanisms in 
cancer patients and the human population. J Am Coll Nutr 
20:464S–472S (discussion 473S–475S)
 24. D’Andrea GM (2005) Use of antioxidants during chemother-
apy and radiotherapy should be avoided. CA Cancer J Clin 
55:319–321
 25. Conklin KA (2000) Dietary antioxidants during cancer chemo-
therapy: impact on chemotherapeutic effectiveness and devel-
opment of side effects. Nutr Cancer 37:1–18. https ://doi.
org/10.1207/s1532 7914n c3701 _1
 26. Pathak AK, Singh N, Khanna N, Reddy VG, Prasad KN, 
Kochupillai V (2002) Potentiation of the effect of paclitaxel and 
carboplatin by antioxidant mixture on human lung cancer h520 
cells. J Am Coll Nutr 21:416–421
 27. Pathak AK, Bhutani M, Guleria R, Bal S, Mohan A, Mohanti 
BK, Sharma A, Pathak R, Bhardwaj NK, Prasad KN, Kochupillai 
V (2005) Chemotherapy alone vs. chemotherapy plus high dose 
multiple antioxidants in patients with advanced non small cell 
lung cancer. J Am Coll Nutr 24:16–21
 28. Drisko JA, Chapman J, Hunter VJ (2003) The use of antioxidant 
therapies during chemotherapy. Gynecol Oncol 88:434–439
 29. Borek C (2004) Dietary antioxidants and human cancer. Integr 
Cancer Ther 3:333–341. https ://doi.org/10.1177/15347 35404 
27057 8
 30. Szymański P, Lázničková A, Lázniček M, Bajda M, Malaw-
ska B, Markowicz M, Mikiciuk-Olasik E (2012) 2,3-Dihydro-
1H-cyclopenta[b]quinoline derivatives as acetylcholinesterase 
inhibitors—synthesis, radiolabeling and biodistribution. Int J 
Mol Sci 13:10067–10090. https ://doi.org/10.3390/ijms1 30810 
067
 31. Olszewska P, Szymański J, Mikiciuk-Olasik E, Szymański P 
(2014) New cyclopentaquinoline derivatives with fluoroben-
zoic acid induce G1 arrest and apoptosis in human lung ade-
nocarcinoma cells. Eur J Pharmacol 729:30–36. https ://doi.
org/10.1016/j.ejpha r.2014.02.003
 32. Velika B, Kron I (2012) Antioxidant properties of benzoic acid 
derivatives against superoxide radical. Free Radic Antiox 2:62–
67. https ://doi.org/10.5530/ax.2012.4.11
 33. Skibiński R, Czarnecka K, Girek M, Bilichowski I, Chufarova N, 
Mikiciuk-Olasik E, Szymański P (2018) Novel tetrahydroacrid-
ine derivatives with iodobenzoic acid moiety as multifunctional 
acetylcholinesterase inhibitors. Chem Biol Drug Des 91(2):505–
518. https ://doi.org/10.1111/cbdd.13111 
 34. Szymański P, Skibiński R, Inglot T, Bajda M, Jończyk J, Malaw-
ska B, Mikiciuk-Olasik E (2013) New tacrine analogs as acetyl-
cholinesterase inhibitors—theoretical study with chemometric 
analysis. Molecules. https ://doi.org/10.3390/molec ules1 80328 78
 35. Lu H, Li X, Zhang J, Shi HUI, Zhu X, He X (2014) Effects of 
cordycepin on HepG2 and EA.hy926 cells: potential antiprolif-
erative, antimetastatic and anti-angiogenic effects on hepatocellu-
lar carcinoma. Oncol Lett 7:1556–1562. https ://doi.org/10.3892/
ol.2014.1965
 36. Ciamporcero E, Daga M, Pizzimenti S, Roetto A, Dianzani C, 
Compagnone A, Palmieri A, Ullio C, Cangemi L, Pili R, Bar-
rera G (2018) Crosstalk between Nrf2 and YAP contributes to 
maintaining the antioxidant potential and chemoresistance in 
bladder cancer. Free Radic Biol Med 115:447–457. https ://doi.
org/10.1016/j.freer adbio med.2017.12.005
 37. Plumb JA (2004) Cell sensitivity assays: the MTT assay. In: 
Langdon SP (ed) Cancer cell culture: methods and protocols. 
Humana Press, Totowa, pp 165–169
 38. Daga M, Pizzimenti S, Dianzani C, Cucci MA, Cavalli R, Grat-
tarola M, Ferrara B, Scariot V, Trotta F, Barrera G (2019) Ailan-
thone inhibits cell growth and migration of cisplatin resistant 
bladder cancer cells through down-regulation of Nrf2, YAP, 
and c-Myc expression. Phytomedicine 56:156–164. https ://doi.
org/10.1016/j.phyme d.2018.10.034
 39. Chen L-m, Peng F, Li G-d, Jie X-m, Cai K-r, Cai C, Zhong Y, 
Zeng H, Li W, Zhang Z, Chen J-c (2016) The studies on the 
cytotoxicity in vitro, cellular uptake, cell cycle arrest and apop-
tosis-inducing properties of ruthenium methylimidazole complex 
[Ru(MeIm)4(p-cpip)]2+. J Inorg Biochem 156:64–74. https ://
doi.org/10.1016/j.jinor gbio.2015.12.016
 40. Michel P, Owczarek A, Matczak M, Kosno M, Szymanski P, 
Mikiciuk-Olasik E, Kilanowicz A, Wesolowski W, Olszewska 
MA (2017) Metabolite profiling of eastern teaberry (Gaultheria 
procumbens L.) lipophilic leaf extracts with hyaluronidase and 
lipoxygenase inhibitory activity. Molecules 22:412/1–412/16. 
https ://doi.org/10.3390/molec ules2 20304 12
 41. González-Muñoz GC, Arce MP, López B, Pérez C, Romero A, 
Barrio Ld, Martín-de-Saavedra MD, Egea J, León R, Villar-
roya M, López MG, García AG, Conde S, Rodríguez-Franco 
MI (2011) N-Acylaminophenothiazines: neuroprotective agents 
displaying multifunctional activities for a potential treatment of 
Alzheimer’s disease. Eur J Med Chem 46:2224–2235. https ://doi.
org/10.1016/j.ejmec h.2011.03.003
 42. Romero A, Egea J, González-Muñoz GC, Martı́n de Saavedra 
MD, del Barrio L, Rodríguez-Franco MI, Conde S, López MG, 
Villarroya M, de los Ríos C (2014) ITH12410/SC058: a new 
neuroprotective compound with potential in the treatment of alz-
heimer’s disease. ACS Chem Neurosci 5:770–775. https ://doi.
org/10.1021/cn500 131t
 43. Plsikova J, Janovec L, Koval J, Ungvarsky J, Mikes J, Jend-
zelovsky R, Fedorocko P, Imrich J, Kristian P, Kasparkova J, 
Brabec V, Kozurkova M (2012) 3,6-Bis(3-alkylguanidino)acri-
dines as DNA-intercalating antitumor agents. Eur J Med Chem 
57:283–295. https ://doi.org/10.1016/j.ejmec h.2012.09.020
 44. Laurora S, Pizzimenti S, Briatore F, Fraioli A, Maggio M, Reffo 
P, Ferretti C, Dianzani MU, Barrera G (2003) Peroxisome pro-
liferator-activated receptor ligands affect growth-related gene 
expression in human leukemic cells. J Pharmacol Exp Ther 
305:932
 45. Pajouhesh H, Lenz GR (2005) Medicinal chemical properties of 
successful central nervous system drugs. NeuroRx 2:541–553
 46. da Silva CHTP, Campo VL, Carvalho I, Taft CA (2006) Molec-
ular modeling, docking and ADMET studies applied to the 
design of a novel hybrid for treatment of Alzheimer’s disease. 
J Mol Graph Model 25:169–175. https ://doi.org/10.1016/j.
jmgm.2005.12.002
 47. Oset-Gasque MJ, González MP, Pérez-Peña J, García-Font N, 
Romero A, Pino Jd, Ramos E, Hadjipavlou-Litina D, Soriano E, 
Chioua M, Samadi A, Raghuvanshi DS, Singh KN, Marco-Con-
telles J (2014) Toxicological and pharmacological evaluation, 
antioxidant, ADMET and molecular modeling of selected race-
mic chromenotacrines 11-amino-12-aryl-8,9,10,12-tetrahydro-
7H-chromeno[2,3-b]quinolin-3-ols for the potential prevention 
and treatment of Alzheimer’s disease. Eur J Med Chem 74:491–
501. https ://doi.org/10.1016/j.ejmec h.2013.12.021
 48. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Exper-
imental and computational approaches to estimate solubility and 
149Molecular and Cellular Biochemistry (2019) 460:123–150 
1 3
permeability in drug discovery and development settings1PII of 
original article: S0169–409X(96), 00423–1. The article was orig-
inally published in Advanced Drug Delivery Reviews 23 (1997) 
3–25.1. Adv Drug Deliv Rev 46:3–26. https ://doi.org/10.1016/
S0169 -409X(00)00129 -0
 49. Meanwell NA (2011) Improving drug candidates by design: a 
focus on physicochemical properties as a means of improving 
compound disposition and safety. Chem Res Toxicol 24:1420–
1456. https ://doi.org/10.1021/tx200 211v
 50. Nikolic K, Filipic S, Smolinski A, Kaliszan R, Agbaba D (2013) 
Partial least square and hierarchical clustering in ADMET 
modeling: prediction of blood-brain barrier permeation of 
α-adrenergic and imidazoline receptor ligands. J Pharm Pharm 
Sci 16:622–647. https ://doi.org/10.18433 /j3jk5 p
 51. Bakhtyari NG, Raitano G, Benfenati E, Martin T, Young 
D (2013) Comparison of in silico models for prediction of 
mutagenicity. J Environ Sci Health C 31:45–66. https ://doi.
org/10.1080/10590 501.2013.76357 6
 52. Wang S, Li Y, Wang J, Chen L, Zhang L, Yu H, Hou T (2012) 
ADMET evaluation in drug discovery. 12. development of binary 
classification models for prediction of hERG potassium chan-
nel blockage. Mol Pharm 9:996–1010. https ://doi.org/10.1021/
mp300 023x
 53. Zhu B-Y, Jia ZJ, Zhang P, Su T, Huang W, Goldman E, Tumas D, 
Kadambi V, Eddy P, Sinha U, Scarborough RM, Song Y (2006) 
Inhibitory effect of carboxylic acid group on hERG binding. 
Bioorg Med Chem Lett 16:5507–5512. https ://doi.org/10.1016/j.
bmcl.2006.08.039
 54. Ramakrishnan P (2003) The role of P-glycoprotein in the blood-
brain barrier. Einstein Q J Biol Med 19:160–165
 55. Poongavanam V, Haider N, Ecker GF (2012) Fingerprint-based 
in silico models for the prediction of P-glycoprotein substrates 
and inhibitors. Bioorg Med Chem 20:5388–5395. https ://doi.
org/10.1016/j.bmc.2012.03.045
 56. Leu B-L, Huang J-d (1995) Inhibition of intestinal P-glycoprotein 
and effects on etoposide absorption. Cancer Chemother Pharma-
col 35:432–436. https ://doi.org/10.1007/s0028 00050 258
 57. Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, Harrell 
PM, Trinh YT, Zhang Q, Urbatsch IL, Chang G (2009) Structure 
of P-glycoprotein reveals a molecular basis for poly-specific drug 
binding. Science 323:1718–1722. https ://doi.org/10.1126/scien 
ce.11687 50
 58. Chen L, Li Y, Yu H, Zhang L, Hou T (2012) Computational 
models for predicting substrates or inhibitors of P-glycoprotein. 
Drug Discov Today 17:343–351. https ://doi.org/10.1016/j.drudi 
s.2011.11.003
 59. Prachayasittikul V, Prachayasittikul V (2016) P-glycoprotein 
transporter in drug development. EXCLI J 15:113–118. https ://
doi.org/10.17179 /excli 2015-768
 60. Chaitanya GV, Alexander JS, Babu PP (2010) PARP-1 cleav-
age fragments: signatures of cell-death proteases in neu-
rodegeneration. Cell Commun Signal 8:31. https ://doi.
org/10.1186/1478-811X-8-31
 61. Galluzzi L, Joza N, Tasdemir E, Maiuri MC, Hengartner M, 
Abrams JM, Tavernarakis N, Penninger J, Madeo F, Kroemer G 
(2008) No death without life: vital functions of apoptotic effec-
tors. Cell Death Differ 15:1113–1123. https ://doi.org/10.1038/
cdd.2008.28
 62. Cotter TG (2009) Apoptosis and cancer: the genesis of a research 
field. Nat Rev Cancer 9:501. https ://doi.org/10.1038/nrc26 63
 63. Gach K, Modranka J, Szymański J, Pomorska D, Krajewska U, 
Mirowski M, Janecki T, Janecka A (2016) Anticancer properties 
of new synthetic hybrid molecules combining naphtho[2,3-b]
furan-4,9-dione or benzo[f]indole-4,9-dione motif with phos-
phonate subunit. Eur J Med Chem 120:51–63. https ://doi.
org/10.1016/j.ejmec h.2016.05.002
 64. Sahu U, Sidhar H, Ghate PS, Advirao GM, Raghavan SC, 
Giri RK (2013) A novel anticancer agent, 8-methoxypyrim-
ido[4′,5′:4,5]thieno(2,3-b) quinoline-4(3H)-one induces neuro 
2a neuroblastoma cell death through p53-dependent, caspase-
dependent and -independent apoptotic pathways. PLoS ONE 
8:e66430. https ://doi.org/10.1371/journ al.pone.00664 30
 65. Margolin N, Raybuck SA, Wilson KP, Chen W, Fox T, Gu Y, 
Livingston DJ (1997) Substrate and inhibitor specificity of 
interleukin-1β-converting enzyme and related caspases. J Biol 
Chem 272:7223–7228. https ://doi.org/10.1074/jbc.272.11.7223
 66. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earn-
shaw WC (1994) Cleavage of poly(ADP-ribose) polymerase by 
a proteinase with properties like ICE. Nature 371:346. https ://
doi.org/10.1038/37134 6a0
 67. Soldani C, Lazzè MC, Bottone MG, Tognon G, Biggiogera M, 
Pellicciari CE, Scovassi AI (2001) Poly(ADP-ribose) polymer-
ase cleavage during apoptosis: when and where? Exp Cell Res 
269:193–201. https ://doi.org/10.1006/excr.2001.5293
 68. D’Amours D, Sallmann FR, Dixit VM, Poirier GG (2001) Gain-
of-function of poly(ADP-ribose) polymerase-1 upon cleavage 
by apoptotic proteases: implications for apoptosis. J Cell Sci 
114:3771
 69. Smulson ME, Pang D, Jung M, Dimtchev A, Chasovskikh S, 
Spoonde A, Simbulan-Rosenthal C, Rosenthal D, Yakovlev A, 
Dritschilo A (1998) Irreversible binding of poly(ADP)ribose 
polymerase cleavage product to DNA ends revealed by atomic 
force microscopy: possible role in apoptosis. Cancer Res 58:3495
 70. Kuo LJ, Yang L-X (2008) γ-H2AX—a novel biomarker for DNA 
double-strand breaks. Vivo 22:305–309
 71. Matthaios D, Hountis P, Karakitsos P, Bouros D, Kakolyris S 
(2013) H2AX a promising biomarker for lung cancer: a review. 
Cancer Invest 31:582–599. https ://doi.org/10.3109/07357 
907.2013.84972 1
 72. Podhorecka M, Skladanowski A, Bozko P (2010) H2AX 
phosphorylation: its role in DNA damage response and 
cancer therapy. J Nucleic Acids 2010:920161. https ://doi.
org/10.4061/2010/92016 1
 73. Salvamani S, Gunasekaran B, Shukor MY, Shaharuddin NA, 
Sabullah MK, Ahmad SA (2016) Anti-HMG-CoA reductase, 
antioxidant, and anti-inflammatory activities of Amaranthus 
viridis leaf extract as a potential treatment for hypercholester-
olemia. J Evid Based Complement Altern Med 2016:10. https ://
doi.org/10.1155/2016/80908 41
 74. de Santana Souza MT, Almeida JRGdS, de Souza Araujo AA, 
Duarte MC, Gelain DP, Moreira JCF, dos Santos MRV, Quin-
tans-Junior LJ (2014) Structure-activity relationship of terpe-
nes with anti-inflammatory profile—a systematic review. Basic 
Clin Pharmacol Toxicol 115:244–256. https ://doi.org/10.1111/
bcpt.12221 
 75. Nishida Y, Sugahara S, Wada K, Toyohisa D, Tanaka T, Ono 
M, Yasuda S (2014) Inhibitory effects of the ethyl acetate 
extract from bulbs of Scilla scilloides on lipoxygenase and hya-
luronidase activities. Pharm Biol 52:1351–1357. https ://doi.
org/10.3109/13880 209.2014.89114 0
 76. Zeng H-j, Ma J, Yang R, Jing Y, Qu L-b (2015) Molecular inter-
actions of flavonoids to hyaluronidase: insights from spectro-
scopic and molecular modeling studies. J Fluoresc 25:941–959. 
https ://doi.org/10.1007/s1089 5-015-1576-3
 77. Shaikh R, Pund M, Dawane A, Iliyas S (2014) Evaluation of 
anticancer, antioxidant, and possible anti-inflammatory prop-
erties of selected medicinal plants used in indian traditional 
medication. J Tradit Complement Med 4:253–257. https ://doi.
org/10.4103/2225-4110.12890 4
 78. Martin-Cordero C, Leon-Gonzalez AJ, Calderon-Montano JM, 
Burgos-Moron E, Lopez-Lazaro M (2012) Pro-oxidant natural 
150 Molecular and Cellular Biochemistry (2019) 460:123–150
1 3
products as anticancer agents. Curr Drug Targets 13:1006–1028. 
https ://doi.org/10.2174/13894 50128 02009 044
 79. Newhouse K, Hsuan S-L, Chang SH, Cai B, Wang Y, Xia Z 
(2004) Rotenone-induced apoptosis is mediated By p38 and JNK 
MAP kinases in human dopaminergic SH-SY5Y cells. Toxicol 
Sci 79:137–146. https ://doi.org/10.1093/toxsc i/kfh08 9
 80. Orozco C, García-de-Diego AM, Arias E, Hernández-Guijo JM, 
García AG, Villarroya M, López MG (2006) Depolarization pre-
conditioning produces cytoprotection against veratridine-induced 
chromaffin cell death. Eur J Pharmacol 553:28–38. https ://doi.
org/10.1016/j.ejpha r.2006.08.084
 81. León R, de los Ríos C, Marco-Contelles J, López MG, García 
AG, Villarroya M (2008) Synthesis of 6-amino-1,4-dihydro-
pyridines that prevent calcium overload and neuronal death. 
Eur J Med Chem 43:668–674. https ://doi.org/10.1016/j.ejmec 
h.2007.06.001
 82. Valero T, del Barrio L, Egea J, Cañas N, Martínez A, García AG, 
Villarroya M, López MG (2009) NP04634 prevents cell dam-
age caused by calcium overload and mitochondrial disruption in 
bovine chromaffin cells. Eur J Pharmacol 607:47–53. https ://doi.
org/10.1016/j.ejpha r.2009.02.021
 83. Zhang B, Li X, Li B, Gao C, Jiang Y (2014) Acridine and its 
derivatives: a patent review (2009–2013). Expert Opin Ther Pat 
24:647–664. https ://doi.org/10.1517/13543 776.2014.90205 2
 84. Wainwright M (2001) Acridine—a neglected antibacterial 
chromophore. J Antimicrob Chemother 47:1–13. https ://doi.
org/10.1093/jac/47.1.1
 85. Joy RJ (1999) Malaria in American troops in the South and 
Southwest Pacific in World War II. Med Hist 43:192–207
 86. B Arimondo P, Hélène C (2001) Design of new anti-cancer 
agents based on topoisomerase poisons targeted to specific DNA 
sequences. Curr Med Chem Anticancer Agents 1(3):219–235. 
https ://doi.org/10.2174/15680 11013 35464 2
 87. Schiller JH (2001) Current standards of care in small-cell and 
non-small-cell lung cancer. Oncology 61(Suppl 1):3–13. https 
://doi.org/10.1159/00005 5386
 88. Song D, Zhao J, Su C, Jiang Y, Hou J (2018) Etoposide induced 
NMI promotes cell apoptosis by activating the ARF-p53 signal-
ing pathway in lung carcinoma. Biochem Biophys Res Commun 
495:368–374. https ://doi.org/10.1016/j.bbrc.2017.10.010
 89. Pardini B, Kumar R, Naccarati A, Novotny J, Prasad RB, Forsti 
A, Hemminki K, Vodicka P, Lorenzo Bermejo J (2011) 5-Fluo-
rouracil-based chemotherapy for colorectal cancer and MTHFR/
MTRR genotypes. Br J Clin Pharmacol 72:162–163. https ://doi.
org/10.1111/j.1365-2125.2010.03892 .x
 90. Longley DB, Harkin DP, Johnston PG (2003) 5-fluorouracil: 
mechanisms of action and clinical strategies. Nat Rev Cancer 
3:330–338. https ://doi.org/10.1038/nrc10 74
 91. Wolpin BM, Mayer RJ (2008) Systemic treatment of colo-
rectal cancer. Gastroenterology 134:1296–1310. https ://doi.
org/10.1053/j.gastr o.2008.02.098
 92. Tawfik E, Ahamed M, Almalik A, Alfaqeeh M, Alshamsan A 
(2017) Prolonged exposure of colon cancer cells to 5-fluoroura-
cil nanoparticles improves its anticancer activity. Saudi Pharm J 
25:206–213. https ://doi.org/10.1016/j.jsps.2016.05.010
 93. Lee S, Shim JH, Gim H, Park HS, Kim BJ (2016) Ethanol extract 
of Oldenlandia diffusa—an effective chemotherapeutic for the 
treatment of colorectal cancer in humans: anti-cancer effects of 
Oldenlandia diffusa. J Pharmacopunct 19:51–58. https ://doi.
org/10.3831/kpi.2016.19.007
 94. Shankaraiah N, Nekkanti S, Chudasama KJ, Senwar KR, Sharma 
P, Jeengar MK, Naidu VGM, Srinivasulu V, Srinivasulu G, 
Kamal A (2014) Design, synthesis and anticancer evaluation of 
tetrahydro-β-carboline-hydantoin hybrids. Bioorg Med Chem 
Lett 24:5413–5417. https ://doi.org/10.1016/j.bmcl.2014.10.038
 95. Ulukaya E, Ozdikicioglu F, Oral AY, Demirci M (2008) The 
MTT assay yields a relatively lower result of growth inhibition 
than the ATP assay depending on the chemotherapeutic drugs 
tested. Toxicol In Vitro 22:232–239. https ://doi.org/10.1016/j.
tiv.2007.08.006
 96. Soultati A, Mountzios G, Avgerinou C, Papaxoinis G, Pectasides 
D, Dimopoulos MA, Papadimitriou C (2012) Endothelial vascu-
lar toxicity from chemotherapeutic agents: preclinical evidence 
and clinical implications. Cancer Treat Rev 38:473–483. https ://
doi.org/10.1016/j.ctrv.2011.09.002
 97. Walker PR, Smith C, Youdale T, Leblanc J, Whitfield JF, Sikor-
ska M (1991) Topoisomerase II-reactive chemotherapeutic drugs 
induce apoptosis in thymocytes. Cancer Res 51:1078–1085
 98. Lock RB, Stribinskiene L (1996) Dual modes of death induced by 
etoposide in human epithelial tumor cells allow Bcl-2 to inhibit 
apoptosis without affecting clonogenic survival. Cancer Res 
56:4006–4012
 99. Mailloux A, Grenet K, Bruneel A, Beneteau-Burnat B, Vau-
bourdolle M, Baudin B (2001) Anticancer drugs induce 
necrosis of human endothelial cells involving both onco-
sis and apoptosis. Eur J Cell Biol 80:442–449. https ://doi.
org/10.1078/0171-9335-00171 
 100. Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale 
G, Giavazzi R, Taraboletti G (1996) The microtubule-affecting 
drug paclitaxel has antiangiogenic activity. Clin Cancer Res 
2:1843–1849
 101. Vacca A, Iurlaro M, Ribatti D, Minischetti M, Nico B, Ria R, 
Pellegrino A, Dammacco F (1999) Antiangiogenesis is produced 
by nontoxic doses of vinblastine. Blood 94:4143–4155
 102. Tang J-J, He Q-R, Dong S, Guo X, Wang Y-G, Lei B-L, Tian 
J-M, Gao J-M (2018) Diversity modification and structure-activ-
ity relationships of two natural products 1β-hydroxy alantolac-
tone and ivangustin as potent cytotoxic agents. Sci Rep 8:1722. 
https ://doi.org/10.1038/s4159 8-018-20192 -9
 103. Gottesman MM (2002) Mechanisms of cancer drug resistance. 
Annu Rev Med 53:615–627. https ://doi.org/10.1146/annur 
ev.med.53.08290 1.10392 9
 104. Sitko JC, Yeh B, Kim M, Zhou H, Takaesu G, Yoshimura A, 
McBride WH, Jewett A, Jamieson CA, Cacalano NA (2008) 
SOCS3 regulates p21 expression and cell cycle arrest in 
response to DNA damage. Cell Signal 20:2221–2230. https ://
doi.org/10.1016/j.cells ig.2008.08.011
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
